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Abstract 
Dihydrofolate reductase (DHFR) serves an important role in metabolism by 
reducing dihydrofolate (DHF) to the product tetrahydrofolate via hydride transfer from 
NADPH. R67 DHFR, a plasmid encoded form of the enzyme which provides resistance 
to trimethoprim, functions as a homotetramer with D2 symmetry.  Both ligands, DHF and 
NADPH, interact within a 25Ǻ active site pore.  Mutagenesis of one active site residue 
results in four-symmetry related mutations causing large effects on binding and catalysis.  
A construct containing four copies of the DNA for R67 DHFR ligated in-frame and 
flanked by unique restriction sites was engineered and asymmetric mutants were built 
using this construct.  Q67H asymmetric mutants were built with the goal of preserving 
tight binding without inhibition, as Q67H R67 DHFR binds both DHF and NADPH with 
greater affinity than the wild-type enzyme, but also yields severe DHF and NADPH 
inhibition [Park, H., Bradrick, T. D., and Howell, E. E. (1997) Protein Eng. 10, 1415-
1424].  Although many of the Q67H asymmetric mutants bind NADPH with greater 
affinity than the control, inhibition is often observed.  From these studies, a role for Q67 
in selecting for the productive ternary complex over inhibitory complexes was proposed.  
Asymmetric Y69F mutants were also generated, as the kcat for Y69F R67 DHFR is 
increased 2 fold compared to the wild-type enzyme, while the Km values are increased 
[Strader, M. B., Smiley, R. D., Stinnett, L. G., VerBerkmoes, N. C., and Howell, E. E. 
(2001) Biochemistry 40, 11344-11352].  These asymmetric mutants were constructed 
with the goal of increasing kcat while maintaining high affinity.  Although this goal was 
not accomplished, these asymmetric mutants provided insight into ligand binding and 
catalysis in R67 DHFR as they support a model where two Y69 residues interact with 
 iv
NADPH, while mutations along the dimer-dimer interface increasing kcat.  Thus, 
generating asymmetric mutants of R67 DHFR has provided a means by which to 
understand ligand binding and catalysis in a homotetrameric enzyme where only a single 
active site pore is available.    
 v
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Part I:  A Background to R67 Dihydrofolate Reductase 
 1
Antibiotic Resistance and R-plasmid DHFRs 
For several decades, drug companies have focused much attention on synthesis of 
antibiotics which specifically target microbial cells (1).  Antibiotics have been designed 
to target several pathways in the microbial cell, ranging from pathways involved in 
generation of the cell wall to pathways involved in metabolism of folate (2).  Along with 
the increase in use of the antibiotics came the realization that bacteria were able to 
acquire resistance mechanisms which rendered the antibiotics ineffective (1).  Although 
several such resistance mechanisms have since been discovered, one particularly 
interesting mechanism was identified in the 1970s in patients with bacterial infections 
whose treatment involved use of the antibiotic trimethoprim (TMP) (3-7).  In these 
studies, chromosomal (bacterial) dihydrofolate reductase (DHFR), an enzyme involved in 
folate metabolism, was the antibiotic target (3-7).  Bacterial cells resistant to TMP were 
found to contain an R-plasmid (or resistance plasmid) which afforded the resistance 
mechanism.  Interestingly, the R-plasmid contains the gene for a form of DHFR which 
was not susceptible to TMP.  Since the plasmid-encoded enzyme catalyzed the same 
reaction as the chromosomal enzyme, bacterial cells were able to survive in the presence 
of TMP even though their own DHFR was inhibited (5, 6). 
Subsequent studies have determined that several distinct R-plasmid encoded 
DHFRs exist.  These R-plasmids have been categorized based on amino acid sequence 
comparisons into 5 groups designated A-E.  Of these five groups, one group, C, is 
particularly interesting in that the amino acid sequences of members of this group are 
rather dissimilar from those of the other groups ((8) and references therein).  Group C 
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consists of R-plasmid DHFRs classified as Type II DHFRs (8).  Type II DHFRs are also 
interesting from a clinical perspective due to their lack of sensitivity to TMP (9, 10).   
 One R-plasmid DHFR of particular interest in our laboratory is R67 DHFR.  R67 
DHFR is classified as a Type II R-plasmid encoded enzyme, distinguished along with 
other Type II enzymes by its lack of sensitivity to TMP (9).  Surprising to researchers at 
the time of its discovery is that the enzyme shares no genetic homology with any 
dihydrofolate reductases (10).  Interestingly, studies also indicated that R67 DHFR exists 
as a homotetramer (7).  
DHFR:  Metabolic Function 
 What functional role does DHFR play in metabolism?  Dihydrofolate reductase 
catalyzes the transfer of a hydride ion from the cofactor, NADPH, to the substrate, 7,8-
dihydrofolate, forming 5,6,7,8-tetrahydrofolate.  This reaction is illustrated in Figure 1.  It 
plays an important role in single-carbon metabolism, a pathway important in generation 
of purine nucleotides as well as other metabolites.  As such, the enzyme’s function is 
important to the survival of the cell.  Thus, dihydrofolate reductases have been the target 
of both antibiotic as well as anti-cancer drugs (11).  
DHFR:  Ligand Structures  
 Chemical structures for the ligands, NADPH and folate, are shown in Figure 2.  
Both NADPH and NADH are composed of the following moieties:  an adenine ring, two 
ribose rings connected by a pyrophosphate bridge, and a nicotinamide ring.  The 
chemical reaction, or hydride transfer, occurs at the C4 (carbon four) position of the 
nicotinamide ring.  NADH and NADPH are distinguished by the presence of a phosphate 
group at the 2′ position of the ribose ring (adjacent to the adenine ring) in NADPH that is 
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Figure 1.  Metabolic pathway involving dihydrofolate reductase.  Modified from 
(11). 
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Figure 2.  Chemical structures of ligands recognized by DHFR including folate and 
NADPH.  Taken from (12). 
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not present in NADH.  Instead, the ribose ring of NADH is unmodified, containing a 
hydroxyl group at its 2′ position (11).  DHF and folate are composed of a pteridine ring, a 
para-aminobenzoic acid moiety (pABA), and a glutamic acid moiety (12).  For both DHF 
and folate, the chemical reaction occurs on the pteridine ring.  DHF and folate are 
distinguished by a reduction of folate’s C7-N8 (carbon seven-nitrogen 8) double bond 
generating DHF.  DHFR catalyzes the reduction of both folate to 7,8-DHF as well as the 
reduction of 7,8-DHF to 5,6,7,8-tetrahydrofolate (11).  However, in R67 DHFR, the 
efficiency of the former is greatly reduced in comparison to the latter (Howell, personal 
communication).  For comparative purposes, the pyrophosphate-ribose-adenine moieties 
of NADPH will be referred to as the NADPH tail while the ribose-nicotinamide moieties 
will be referred to as the NADPH head.  Similarly, the pteridine ring of DHF will be 
referred to as the DHF head and the pABA-glutamic acid moieties will be referred to as 
the pABA-glu tail (12).   
R67 DHFR:  Stereochemistry of Hydride Transfer 
 In oxidoreductase reactions, hydride transfer from NADPH or NADH to the 
ligand is stereospecific.  Dehydrogenases are often categorized as being either A-specific 
or B-specific based on the stereochemistry of the transfer.  A-specific dehydrogenases 
catalyze the transfer of the pro-R hydrogen at carbon-4 of NADPH (or NADH) to the 
ligand.  In contrast, B-specific dehydrogenases catalyze the transfer of the pro-S 
hydrogen at carbon-4 of NADPH (or NADH).  The two classes of enzymes are also 
distinguished in respect to the orientation of the cofactor within the active site.  In A- 
specific dehydrogenases, the ribonicotinamide bond is located in an orientation anti to the 
carbon-3 amide substituent of the nicotinamide moiety.  This orientation is syn for B- 
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specific dehydrogenases ((13) and references therein).  For R67 DHFR, isotope studies 
where the kinetics of hydride transfer are monitored when NADPD is substituted for 
NADPH indicate that the pro-R hydrogen is transferred during the reaction (14, 15).  
However, in contrast to other dehydrogenases, NMR studies suggest that the 
ribonicotinamide bond is in a syn conformation in the active site (16).      
R67 DHFR:  Structure 
The first crystal structure solved for the R67 DHFR was that of the dimer (17).  
Chymotrypsin cleavage of the first 16 amino acids of each monomer (18) facilitated 
crystallization of the active form of the enzyme, the homotetramer (19).  This structure, 
illustrated in Figure 3, indicates that R67 DHFR is a D2 symmetric enzyme possessing 
222 symmetry.  Structural evidence also indicates that the enzyme is a β-barrel protein 
where each monomer is composed of five β-strands in an antiparallel orientation.  
Assembly of each of the four monomers yields a 25Å pore that extends through the 
center of the enzyme.  Two pairs of symmetry-related glutamine 67 residues hydrogen-
bond generating a “floor” and “ceiling” to the pore (19). 
R67 DHFR:  Ligand Binding in the Active Site 
 In addition to the crystal structure for the apoenzyme, a crystal structure has also 
been solved for an enzyme-folate complex.  In this structure, the pteridine ring of one  
folate molecule (designated FolI) interacts near the pore’s center such that its si face is 
available for hydride transfer.  A second folate molecule (designated FolII) binds further 
out from the pore’s center in an orientation that prevents access to its si face for hydride 
transfer.  In contrast to the electron density observed for the pteridine rings for FolI and 
FolII, diffuse electron density is observed for the pABA-glu tails of the two molecules.   
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Figure 3.  Front view of R67 DHFR crystal structure (protein data bank 1VIE).  
Monomers were originally labeled clockwise as ABDC and have been relabeled 1234, 
where monomer 1 is green, monomer 2 is yellow, monomer 3 is magenta, and monomer 
4 is cyan. 
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This density orients the two pABA-glu tails in opposite directions away from the pore’s 
center.  The lack of a strong electron density for the tails suggests that the tails lack 
specific contacts with the enzyme’s active site (19).  These data are supported by docking 
studies using the computer programs DOCK version 4.0 and SLIDE version 1.1 (12).  In 
these studies, the substrate, folate, was docked into the highest scoring enzyme·NMN 
(nicotimamide mononucleotide) complex where the stereochemistry of hydride transfer 
from NMN was A-side. (NMN contains the nicotinamide ring, ribose ring, and one 
phosphate group of the NADPH pyrophosphate bridge.)  In most high scoring predictions 
using this software, FolI docked in an orientation similar to that observed in the crystal 
structure.  However, the docked location of the pABA-glu tail was not consistent within 
the highest scoring conformers corresponding to the observed diffuse electron density in 
the crystal structure.  These data suggest that the pABA-glu tail displays some degree of 
mobility within the active site (12, 19).  Li et al. (16) propose that positive transferred 
nuclear Overhauser interactions observed only for the glutamate tail of folate support 
such a model.   
 In contrast to folate, no crystal structure has been determined for NADPH or an 
NADPH moiety (such as NMN) bound to R67 DHFR.  However, NMR studies have 
provided some insight into NADPH binding in the active site of R67 DHFR.  Although 
no specific bonding interactions between the enzyme and cofactor were identified, shifts 
in protein amide resonances upon cofactor (NADP+) binding implicate several amino 
acids as being involved in ligand binding.  Residues proposed by other studies to line the 
active site (12, 19, 20) were most often associated with the greatest chemical shift 
changes upon ligand binding (21).      
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R67 DHFR:  Ligand Interactions in the Active Site 
 NMR studies have provided information regarding how the ligands bind within 
the active site.  In these studies, intraligand interactions are determined by transferred 
nuclear Overhauser effects (NOE’s).  Positive transferred NOE’s for the glutamic acid 
tails of two folate molecules bound within the active site are observed.  Interestingly, in 
the same complex, negative tNOE’s for the pABA and pteridine moieties of folate are 
noted.  Combined, these data suggest that the tail mobile within the active site.  In 
contrast, transferred NOE studies suggest that NADPH binds where the bond between the 
ribose and nicotinamide rings is syn while the bond between the ribose and adenine rings 
is anti (16).   
NMR studies have also revealed information regarding interactions between 
NADPH and DHF, or interligand interactions, in the active site.  These interactions are 
distinguished by studies involving interligand Overhauser effects (ILOE’s) (16).  Based 
on the enzyme-folate complex determined by x-ray crystallography, Narayana et al. (19) 
originally hypothesized that NADPH’s nicotinamide ring would interact between 
glutamine 67 residues comprising the “ceiling” of the enzyme and FolI bound in close 
proximity to the “floor” of the enzyme.  Thus, both DHF and NADPH would bind in a 
single half of the active site pore (16, 19).  In such an orientation, strong interligand 
interactions should occur between the pABA moiety of DHF and the nicotinamide ring of 
NADPH.  These interligand interactions were not observed by NMR studies suggesting 
that such an arrangement of ligands within the active site is unlikely.  In contrast, the 
ILOE data suggest that the nicotinamide and pteridine rings bind near the pore’s center 
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allowing the tail moieties of NADPH and DHF to project away from one another toward 
opposite halves of the active site pore (16). 
R67 DHFR:  Stereochemistry of the Transition State  
 Quantum-mechanical/molecular-mechanical studies have been employed to 
predict the orientation of the pteridine ring of DHF and the nicotinamide ring of NADPH 
during catalysis.  In vacuo studies suggest that two transition state stereochemistries are 
possible, an endo transition state and an exo transition state (22).  Of the two possible 
transition states, an endo transition state yields the greatest overlap of the highest 
occupied molecular orbitals and lowest unoccupied molecular orbitals (23).  As a result, 
the endo transition state is proposed to be 2-8 kcal/mole more stable than the exo 
transition state (22).  Addition of the active site environment to the calculations for E. 
coli DHFR, however, suggests that in this enzyme catalyzed reaction, the exo transition 
state is favored.  Thus, active site interactions allow a transition state, less 
thermodynamically favored in vacuo, to be approached in the enzyme active site (22).  In 
contrast to E. coli DHFR, ILOEs for a folate-NADP+-enzyme complex for R67 DHFR 
support the use of an endo transition state for this enzyme (16). 
R67 DHFR:  No Proton Donor  
Originally, it was proposed that an ionizable moiety is involved in the catalytic 
mechanism for R67 DHFR as a non-linear pH versus rate profile was observed for the 
enzyme.  The pK associated with the pH versus velocity plot was determined to be 5.8 
(18).  It was therefore proposed that ionization of symmetry-related histidine 62 residues, 
located along the dimer-dimer interface of R67 DHFR, may be involved in catalysis.  
However, gel filtration studies indicated that at pH 5, the elution profile of the enzyme 
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represented that of a dimer, whereas at pH 8, the elution profile represented that of a 
tetramer (24).  In addition, steady-state kinetic analysis of dimeric H62C R67 DHFR 
treated with DEPC indicated that the catalytic efficiency of the dimer is affected 200-600 
fold.  These studies indicate that the “bell-shape” nature of the pH versus activity plot is 
therefore due to a disruption of the active tetrameric protein into a less active or inactive 
dimeric protein at acidic pH values (around pH 6) (24).   
What causes the > 100 fold increase in catalytic activity as pH is decreased from 
~10 to ~7 in R67 DHFR (18)?  Comparisons with E. coli DHFR led to the suggestion that 
a proton donor other than histidine 62 may be involved in catalysis.  In E. coli DHFR, 
aspartic acid 27 is proposed to provide a proton to dihydrofolate during catalysis.  
Mutagenesis studies where this residue is replaced with a serine result in a decrease in kcat 
for the reaction (25).   
Does R67, like E. coli DHFR, have a proton donor (26)?  For R67 DHFR, 
symmetry-related tyrosine 69 residues are the only amino acid residues with dissociable 
side chains within the proposed active site that may provide a proton to DHF during 
catalysis.  However, pH versus rate profiles for R67 DHFR indicated that no ionization 
effects are observed around pH 9.5-10, the solution pK of tyrosine (26).  Titration of a 
non-dissociable R67 DHFR mutant (H62C R67 DHFR) with acid yielded a linear pH 
versus rate profile, where kcat increases as pH decreases.  Based on these studies, it was 
determined that, in contrast to E. coli DHFR, there is no proton donor in R67 DHFR, and 
the substrate must be pre-protonated for the reaction to occur (26).   
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R67 DHFR:  Catalytic Mechanism 
Prior to ligand binding and x-ray crystallography studies, it was proposed that due 
to the symmetry of R67 DHFR, four ligands could potentially bind within the large active  
site pore (27, 19).  However, x-ray crystallography studies suggest that a total of two 
folate molecules associate with the enzyme, where steric effects prevent four from 
binding (19).  In addition, ligand binding studies using isothermal titration calorimetry 
and fluorescence anisotropy suggest that steric effects allow a limit of two ligands to bind 
within the active site.  This includes two non-productive complexes where two NADPH 
or two DHF molecules interact with the enzyme.  A single productive, ternary complex 
forms when one NADPH and one DHF molecule interact in the active site (19).   
In addition to the stoichiometric data obtained from these studies, isothermal 
titration calorimetry studies also provided information regarding interaction between 
ligands within the active site, in particular, their cooperative behavior (27).  When the 
binding of one ligand in the active site affects the binding of a second ligand within the 
active site, the two ligands are said to be cooperative.  Two types of cooperativity are 
possible based on the nature of the interactions within the active site.  If one molecule 
binds in a manner that requires the second ligand to display a weaker affinity to the 
enzyme, the interligand interaction is negatively cooperative.  In contrast, if the binding 
of the first ligand allows the second ligand to bind more tightly, the interaction is 
positively cooperative.  Cooperativity patterns between two ligands can be determined by 
dividing the dissociation constant for the second ligand binding event by the dissociation 
constant for the first ligand binding event (i.e. Kd2/Kd1) (20, 27).  When the Kd2/Kd1 value 
is greater than one, the pattern reflects positive cooperativity.  However, when the value 
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is less than one, the pattern of ligand binding suggests negative cooperativity.  If no inter-
ligand cooperativity occurs (i.e. the ligands bind independently of one another), a value 
of one is expected (20, 27).   
Comparison of the Kd values for the first and second NADPH binding events in 
R67 DHFR yielded a Kd2/Kd1 value less than one, suggesting that the two NADPH 
molecules interact in a negatively cooperative fashion within the active site (27).  To 
explain this pattern of cooperativity, it was suggested that the first NADPH molecule 
interacts with the enzyme close to the pore’s center.  This binding was proposed to 
prevent tight binding of a second NADPH molecule in a symmetry related site through 
steric or electrostatic interactions.  In contrast, comparisons of the binding affinities for 
two DHF/folate molecules within the active site indicated that these ligands display 
positive cooperativity.  It was therefore suggested that the first DHF/folate molecule 
binds with weak affinity within the active site.  However, the second DHF molecule 
interacts with both the enzyme and the already bound DHF/folate molecule resulting in 
an increased binding affinity.  In addition, interactions are also proposed to occur 
between NADPH and DHF, bound in the productive, ternary complex.  Specifically, it is 
proposed that positive cooperativity occurs between NADPH and DHF that allows DHF 
to bind with a greater affinity in the productive complex (27).  These studies, in addition 
to steady-state kinetic studies for wild-type R67 DHFR (18), have allowed a mechanism 
for catalysis to be proposed.  A diagram of this mechanism is shown in Figure 4.  Based 
on these studies, it is proposed that R67 DHFR can follow a random bi-substrate 
mechanism, but favors a pathway where NADPH interacts with the enzyme first followed 
by DHF (based on the Kd values and cooperativity patterns).  Cooperativity patterns  
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Figure 4.  Proposed binding scheme for R67 DHFR.  Double arrows represent events in 
equilibrium while the single arrow represents the rate-determining step for the enzyme 
catalyzed reaction.  Taken from (27). 
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between two bound NADPH molecules and two bound DHF molecules disfavor their 
formation in comparison to the active ternary complex.  Thus, substrate and cofactor 
inhibition are not detected for R67 DHFR (18, 27).   Kinetic isotope studies using 
NADPD also show an isotope effect of 3 indicating that the hydride transfer step is rate-
limiting (14). 
R67 DHFR:  Inhibitor Studies 
 In order to better understand the mechanism of R67 DHFR, inhibition studies 
were performed.  In these studies, no inhibition by DHF or NADPH was detected while 
only minor inhibition by tetrahydrofolate was detected.  The substrate, folate, displayed 
competitive inhibition with respect to DHF and noncompetitive inhibition with respect to 
NADPH.  NADP+ was competitive with respect to NADPH and para-uncompetitive with 
respect to DHF.  Based on these inhibitor studies as well as isotope effects indicating that 
hydride transfer is the rate-limiting step for the reaction, it was proposed by Morrison and 
Sneddon that R67 DHFR follows a “Bi-Bi rapid equilibrium, random mechanism” (15). 
R67 DHFR:  Residues Comprising the Active Site Pore 
Docking studies predict that several residues near the active site pore may be 
involved in binding DHF and/or NADPH.  These include lysine 32, serine 65, valine 66, 
glutamine 67, isoleucine 68, and tyrosine 69 (12).  The crystal structure for R67 DHFR 
where the active site residues are highlighted is shown in Figure 5.  The proposed 
contacts between the active site residues and specific moieties of the substrate and 
cofactor based on docking predictions are illustrated in Figure 6.  In attempts to better 
understand how these active site residues are involved in ligand binding and catalysis, 
site-directed mutagenesis studies have been performed, and the mutants have been 
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Figure 5.  Conolly surface map of R67 DHFR.  Active site residues affecting ligand 
binding and/or catalysis are highlighted in blue.  Residues in green have minimal affects 
on ligand binding and catalysis, while magneta residues are important for dimer-dimer 
interactions.  Panel A shows a front view of the Conolly surface map.  Panel B shows a 
view of a single dimer interface generated by dissecting the tetramer in half along the 
dimer-dimer interface.  Panel C is a view of a single monomer interface generated by 
dissecting the tetramer in half along the monomer-monomer interface.  Taken from (30). 
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Figure 6.  Proposed contacts between R67 DHFR active site residues and ligands.  
Taken from (12).  
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characterized (20, 28, 29).  For clarity, the proposed interactions for each of these 
residues will be described followed by the effects of mutagenesis on ligand binding and 
catalysis. 
Lysine 32 
 Docking studies suggest that lysine 32 may provide contacts to the glutamate 
moiety of DHF.  In addition, these studies indicate that a symmetry-related lysine 32 may 
also provide binding contacts to the 2′ phosphate moiety of the cofactor (12).  Lysine 32 
was therefore mutated to methionine.  However, K32M R67 DHFR was unable to be 
characterized kinetically and thermodynamically since the mutations resulted in a dimer 
(28).  This residue will be considered later as the electrostatic potential of the enzyme is 
discussed. 
Serine 65 
 No direct interactions are predicted between serine 65 and either NADPH or 
DHF.  However, docking studies do predict that the –OH group of serine 65 may interact 
via a water mediated hydrogen bond with a ribose hydroxyl group and with a phosphate 
oxygen of NMN (12, 20).  No specific interactions between serine 65 and folate were 
predicted by docking studies.  However, since the hydroxyl group of the residue is 
directed toward the active site, a potential role in hydrogen bonding interactions with the 
ligand was also proposed (12, 20).  Serine 65 was mutated to alanine residue to remove 
its potential for hydrogen bond formation through its side chain.  S65A displayed similar 
kinetic and thermodynamic characteristics to that of the wild-type enzyme.  These data 
suggest that either the serine hydroxyl group is not involved in binding DHF and NADPH 
or that the interactions are not direct (12, 20).   
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Glutamine 67 
 Symmetry-related glutamine 67 residues are proposed to play an important role in 
definition of the active site architecture as x-ray crystallographic data indicate that they 
contribute the “floor” and “ceiling” to the active site (19).  Docking studies also indicate 
that these residues play an important role in binding interactions with both NADPH and 
DHF.  Specifically, it is proposed that hydrogen bonding interactions between a 
glutamine 67 side chain and a ribose hydroxyl group of NMN occur.  In addition, it is 
predicted that van der Waals contacts between glutamine 67 and the nicotinamide moiety 
of NMN occur.  Similar interactions are proposed between symmetry-related glutamine 
67 residues and the folate’s pteridine ring (12, 20).  Symmetry-related glutamine 67 
residues were mutated to histidine residues to generate Q67H R67 DHFR (29) and to 
cysteine residues to generate Q67C R67 DHFR (20).  These mutations both resulted in a 
slower kcat for the reaction.  However, the two mutations had opposite effects on Km(DHF) 
and Km(NADPH).  For Q67H R67 DHFR, Km(DHF) is ~ 25 fold tighter than the wild-type 
value while the Km(NADPH) is ~ 100 fold tighter than R67 DHFR.  In contrast, the Km(DHF) 
for Q67C R67 DHFR increased ~ 9.5 fold while the Km(NADPH) increased ~ 9 fold.  These 
studies suggest that symmetry-related glutamine 67 residues play a role in binding 
NADPH and DHF (12, 20, 29). 
B 
Isoleucine 68 
 Docking studies predict that backbone amide and carboxyl moieties of isoleucine 
68 interact with the nicotinamide ring of NMN while van der Waals contacts are also 
predicted between the residue and NMN.  In addition, the backbone amide of I68 is also 
predicted to interact via a hydrogen bond with the pteridine ring of folate.  A water 
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mediated interaction between the backbone amide of another isoleucine 68 and the 
pteridine ring of folate is proposed as well (12, 20).  Therefore, symmetry-related I68 
residues were mutated in two different experiments to leucine and methionine generating 
I68L R67 DHFR and I68M R67 DHFR, respectively (20).  In both mutants, the Km(DHF) 
values were increased ~ 4 fold while the Km(NADPH) values were increased ~ 7-9 fold.  
Both mutations also resulted in a decrease in kcat for the reaction, with the I68M mutant 
having the most dramatic effect.  Ligand binding studies were also conducted for I68L 
R67 DHFR to determine the effects of the mutations on binding of NADPH to the 
enzyme using isothermal titration calorimetry.  In these studies, the binding of the first 
NADPH is increased ~ 10 fold while the binding of the second NADPH is increased ~ 5 
fold.  These data suggest that symmetry-related I68 residues comprise the binding sites 
for both NADPH and DHF (12, 20). 
Tyrosine 69 
 Docking studies predict formation of two types of interactions between Y69 and 
NMN.  These include a water mediated hydrogen bond between the hydroxyl of the 
residue and a phosphate oxygen of NMN as well as van der Waals contacts between the 
ring edge of the residue and ribose hydroxyl groups of NMN.  A possible interaction 
between tyrosine 69 and folate has also been proposed from docking studies.  
Specifically, a hydrogen bonding interaction is predicted between the hydroxyl of the 
amino acid and the glutamate tail of the ligand (12, 20).  Thus, symmetry-related Y69 
residues were mutated to either phenylalanine residues to generate Y69F R67 DHFR or 
to histidine residues to generate Y69H R67 DHFR (20).  Both mutations increased the 
Km(DHF) to a similar extent, ~ 8 fold.  However, the histidine mutations had a more 
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dramatic effect on the Km(NADPH) value, with a value ~ 59 fold greater than the wild-type 
enzyme versus the 22 fold greater value observed for Y69F R67 DHFR.  Interestingly, 
the effects on kcat were also unique.  For Y69F R67 DHFR, the kcat was increased > 2 fold 
while the reaction rate for Y69H R67 DHFR was ~ 100 fold slower than the wild-type 
enzyme.  Again, these data suggest that Y69 residues comprise a portion of the binding 
sites for both DHF and NADPH (12, 20). 
 R67 DHFR:  “Hot Spot” Binding 
 Site-directed mutagenesis studies of homotetrameric R67 DHFR as well as 
docking studies suggest that R67 DHFR may display a “hot spot” binding mode (12, 20).  
“Hot spot” or “consensus” binding modes are often observed in proteins which recognize 
more that one unique ligand or “partner” (31).  For example, immunoglobulin G (IgG) 
recognizes several unique protein scaffolds.  Comparing the interactions between IgG and 
each of the protein partners reveals that several IgG residues are involved in interactions 
with each of the scaffolds.  In particular, a surface is formed by those residues commonly 
involved in the interactions.  In the IgG surface, the residues comprising the surface have 
a large degree of hydrophobicity (31).  However, other “hot spots” are recognized by 
their amphipathic character (12, 20).  Such is the case for R67 DHFR.  In this enzyme, 
several of the residues proposed to comprise the active site also display some 
amphipathic character.  For example, the side chain of tyrosine 69 is composed of a 
hydrophobic ring as well as a polar hydroxyl group.  Although the R-chains of valine 66 
and isoleucine 68 are non-polar, their amide and carbonyl backbone moieties provide 
polar character since they are also appropriately positioned for interactions with the 
ligands.  In addition, the symmetry of R67 DHFR is important for this “hot spot” binding 
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mode as docking studies indicate that symmetry related residues may play a role in 
binding both ligands.  These studies also suggest that the binding sites for the two ligands 
share some degree of overlap.  Based on these characteristics, R67 DHFR is proposed to 
have a “hot spot” binding mode (12).          
R67 DHFR:  Electrostatic Interactions 
 An electrostatic potential map for R67 DHFR was constructed with the program, 
DELPHI.  These studies indicate that the active site of R67 DHFR is positively charged 
(12).  Since both NADPH and DHF are negatively charged, it was suggested the positive 
charge character of the enzyme draws the ligands towards the active site (12, 28).  A 
large portion of the positive potential is generated by two adjacent residues, lysine 32 and 
lysine 33.  In addition to generating a positive electrostatic potential, docking studies also 
suggest that symmetry-related lysine 32 residues facilitate binding of both DHF and 
NADPH by participating in electrostatic contacts (12).  In order to assess the involvement 
lysine 32 in ligand binding and catalysis, this residue was mutated to both polar and 
nonpolar residues.  Unfortunately, each of the cells expressing these mutants was TMP 
sensitive.  K32A and K32M were further characterized and both decreased the stability of 
the tetramer resulting in inactive dimers.  Studies involving K33M indicate that it is 
active and tetrameric.  In fact, this mutant is similar to wild-type R67 DHFR both 
kinetically and thermodynamically.  It was therefore proposed that this residue 
contributes only weakly to ligand binding and catalysis (28).    
To indirectly address the role of K32 residues in ligand binding and catalysis, salt 
studies were performed on R67 DHFR as well as the K33M mutant.  In these studies, 
increasing concentrations of salt in the buffer medium should interfere with ionic contacts 
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formed between K32 and the ligands.  In these experiments, Km values for both ligands 
increased linearly as the amount of salt in the buffer was increased.  The same trend was 
observed for the kcat for the reaction.  In addition, ligand binding for both folate and 
NADPH was affected by increasing salt concentrations.  Based on these studies, it was 
suggested that K32 forms contacts with the pyrophosphate bridge and 2′ phosphate of 
NADPH.  In addition, these studies indicate that an ionic interaction must be disrupted in 
order to approach the transition state for the reaction (28).            
R67 DHFR:  Other Catalytic Functions 
 In addition to catalyzing the reduction of DHF to tetrahydrofolate, NMR studies 
suggest that R67 DHFR may catalyze two other reactions.  One alternate activity of R67 
DHFR is that of a phosphatase.  Specifically, it has been indicated that R67 DHFR 
catalyzes the conversion of NADP+ to NAD+ over time.  This side reaction is however 
slow (on the order of hours) compared to the catalytic activity of other enzymes (21). 
In addition to its phosphatase activity, NMR studies also indicate the ability of 
R67 DHFR to catalyze a transhydrogenase reaction.  This reactivity stems from the 
enzyme’s ability to bind NADPH and NADP+ simultaneously in a non-productive 
complex (in respect to the enzyme’s dehydrogenase activity).  These studies indicate that 
the enzyme is able to facilitate the transfer of a hydride from the reduced cofactor to the 
oxidized cofactor to an extent (21). 
R67 DHFR:  Generation of the Quad Construct  
 Since R67 DHFR is a tetramer formed by the interaction of four identical 
monomers, site-directed mutagenesis of the gene coding for the monomer results in four 
symmetry-related mutations in the tetramer.  This often has large effects on both ligand 
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binding and catalysis.  Specifically, binding affinities of both DHF and NADPH are often 
both affected by the mutations (20, 28).  Bradrick et al. (27) approached this problem by 
generating the Quad 1 construct which contains four copies of the DNA for the monomer 
associated in-frame.  A schematic of this construct is shown in Figure 7.  The linker 
region between each of the gene copies is the DNA coding for the first 17 amino acids of 
the monomer (32).  These residues are not ordered in the crystal structure for the dimeric 
enzyme and were cleaved facilitating crystallization of the tetramer (17, 19).  In addition, 
chymotrypsin cleavage of the first 16 residues does not alter enzyme activity (18).  Quad 
1 was characterized and compared to wild-type R67 DHFR to ensure that linking the 
genes had not affected protein structure and/or enzyme activity.  Steady-state kinetic 
parameters for the two enzymes were similar suggesting that linking the genes had not 
affected enzyme activity.  In contrast to wild-type R67 DHFR, Quad 1 was unable to 
regain full activity upon refolding following unfolding with guanidine hydrochloride at 
pH 8.  Quad 1, since it is monomeric, is also unable to dissociate into dimers following 
titration with hydrochloric acid.  However, titration can cause the subunits of the 
monomer to “splay out” as symmetry-related histidine 62 residues are protonated.  
Interestingly, these titrations yield a pKa value for symmetry-related histidine 62 residues 
in Quad 1 which is decreased (~ 5.5) with respect to that for R67 DHFR (~ 6.8).  
Although these differences between Quad 1 and R67 DHFR were noted, Quad 1 was still 
considered a good mimic of the homotetrameric enzyme (32). 
One concern regarding Quad 1 was that of its final topology.  In these studies, it 
was predicted that several different topologies were possible for the enzyme.  However, 
in only two of the topologies (ABCD and ABDC) does a linker span the dimer-dimer
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Quad 1 
Gene Copy 3 
ATC-AAC-ATG…….. ATC-AAC-ATG….. ATC-AAC-ATG……..CAC….. 
Bcl1 
ATG-ATC-AAG…TCT.. 
EcoR1
AAC-TAA-TAG-
Gene Copy 1 
I77-N78-M1..….….. I77-N78-M1…...H62L… N78 end 
Gene Copy 2 Gene Copy 4 
Start M1………… S59A……. I77-N78-M1………….
AATG-ATC-AAG…TCT… TC-GAT-ATC……..AGG-TAC-CTC….. AGG-GCC-CTG….CAC… AAC-TAA-TAG- 
Bcl1 EcoR1
Gene Copy 1 
I77-N78-M1..….….. I77-N78-M1…...H62... 
Gene Copy 2 Gene Copy 4 
Start M1………… S59………. N78 end I77-N78-M1………….
Gene Copy 3 
ATC-GAT-ATC……..AGG-TAC-CTC….. AGG-GCC-CTG….CTC… ATG-ATC-AAG…GCT.…. AAC-TAA-TAG- 
Gene Copy 1 
I77-N78-M1..….….. I77-N78-M1…....H62…… 
Gene Copy 2 Gene Copy 4 
Start M1………….. S59………. N78 end I77-N78-M1………….
Gene Copy 3
EcoRI Bcl1 EcoRV 
EcoRV  KpnI
KpnI 
ApaI 
ApaI 
Quad 2 
Quad 3 
Figure 7.  Comparison of Quad gene constructs of R67 DHFR.  The gene copy number is listed above the amino acid 
sequence which is above the nucleotide sequence.  Each gene copy corresponds to a monomer of R67 DHFR.  Quad 1 
contains the DNA encoding the monomers associated in-frame while Quad 2 incorporates unique restriction enzyme sites 
which are highlighted.  Quad 3 contains a S59A and H62L mutation in domains 1 and 4, respectively. Modified from (33). 
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interface a single time.  Of these two topologies, the ABCD topology requires the shortest 
span of the linker region across the dimer-dimer interface suggesting that this topology 
may be favored (32).  A schematic of this is shown in Figure 8 where monomers ABCD 
are renamed as domains 1234 (33).   
Quad 1 was originally constructed as a first step in the goal of generating 
asymmetric mutation.  Since each gene, linked in-frame in Quad 1, is identical, primers 
designed for site-directed mutagenesis studies recognize the same region in every gene.  
Unfortunately, this approach yields four symmetry-related mutations.  As a solution to 
this problem, a new construct was generated.  This construct, named Quad 2, is shown in 
Figure 7.  Quad 2 is similar to Quad 1 in that it also contains four copies of the DNA for 
the R67 DHFR monomer associated in-frame.  Again, the linker region between the 
genes is the DNA coding for the first 17 amino acids of the monomer.  However, each of 
the genes is flanked by unique restriction enzyme sites.  In addition to the Quad 2 
construct, four additional constructs were generated.  These constructs contain a single 
copy of the gene flanked by unique restriction enzyme sites.  An asymmetric mutation 
can be generated by performing site-directed mutagenesis on one of the single copy 
genes.  The plasmid containing the gene is then digested by the appropriate restriction 
enzymes.  At the same time, Quad 2 is also digested with the same restriction enzymes.  
The single gene copy containing the appropriate mutation is then ligated into the Quad 2 
construct (33, Hicks et al., manuscript in preparation).   
Asymmetric mutations of glutamine 67 residues were generated using this system.  
Two of these mutants were characterized kinetically:  Q67H: 1+3 and Q67H: 1+4.  
Before proceeding, it is necessary to explain the nomenclature that will be used to 
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Figure 8.  Schematic of "topology switching" phenomenon.  Panel A illustrates the  
equilibrium proposed between the two topologies of the Quad 2 protein.  Panel B shows 
the shift in equilibrium proposed to occur upon introduction of a S59A mutation in 
domain 1 and an H62L mutation in domain 4.    
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describe the asymmetric mutants throughout this dissertation.  We will identify the wild-
type residue and its position in the monomeric amino acid sequence first.  This will be 
followed by the single letter code for the residue to which it is being mutated.  We will 
then identify the asymmetric location of the mutations.  As shown in Figure 3, we have 
identified each domain of the monomeric Quad 2 construct numerically where domain 1 
occurs in the bottom-left region and the numbering continues in a clock-wise manner.  
Therefore, Q67H: 1+3 contains two glutamine 67 residues mutated to histidine residues.  
The Q67H mutations are located in domain 1 and in domain 3.  Six unique asymmetric 
mutants can be generated using this system, one single mutant, three double mutants, one 
triple mutant, and one quadruple mutant.  These are:  Q67H: 1, Q67H 1+2, Q67H: 1+3, 
Q67H: 1+4, Q67H: 1+2+3, and Q67H: 1+2+3+4.  A schematic of these asymmetric 
mutations is shown in Figure 9 (33).  The same pattern of asymmetric mutations applies 
regardless of the residue mutated.       
 Originally, it was proposed that by generating asymmetric mutations, it might be 
possible to provide unique binding sites for NADPH and DHF (27, 29).  In addition, it 
was proposed that each asymmetric mutant would be unique since each mutant would 
provide a slightly different active site to the ligands.  Therefore, it was proposed that the 
kinetic properties of Q67H: 1+3 and Q67H: 1+4 would be different.  However, initial 
steady- state kinetic evaluation of the mutants indicated that the two were similar 
kinetically.  This led to the conclusion that the Quad constructs may not exist in a single 
topology.  Instead, it was suggested that a “topology-switching” phenomenon may occur.  
If this topology-switching does occur, Q67H: 1+3 and Q67H: 1+4 are no longer unique 
(33).  This is illustrated in Figure 8.        
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 Figure 9. Schematic of unique Q67H asymmetric mutants.  Each sphere represents a 
domain of Quad 3 where each domain is numbered clockwise.  One unique single 
mutant (Q67H: 1), three unique double mutants (Q67H: 1+2, Q67H: 1+3, and Q67H: 
1+4), one unique triple mutant (Q67H: 1+2+3), and one unique quadruple mutant 
(Q67H: 1+2+3+4) are possible using the Quad 3 construct.  Modified from (33). 
Q67H
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 Studies by Dam et al. (34) provided a solution to the “topology-switching” 
problem.  These researchers generated several mutations at serine 59 and histidine 62 in 
homotetrameric R67 DHFR.  These two residues were considered important as they form 
a hydrogen bond that is lost upon protonation of histidine 62 (19, 24).  Protonation of 
symmetry-related 62 residues causes the homotetramer to dissociate resulting in dimers 
(24).  Mutation of symmetry-related serine 59 residues to alanine residues yielded dimers 
that were unable to self-associate as did mutation of symmetry-related histidine 62 
residues to leucine residues.  Interestingly, combining these dimeric mutants in a 1:1 ratio 
generated a heterotetramer with kinetic characteristics similar to that of the wild-type 
protein (33, 34).   
 Based on the findings of Dam et al. (34), a final Quad construct was generated, 
Quad 3.  The Quad 3 construct is shown in Figure 7.  Quad 3 is a modified version of 
Quad 2 which contains two additional mutations:  a S59A mutation in domain 1 and a 
H62L mutation in domain 4.  The Quad 3 construct was used to generate each of the 
asymmetric mutations described in this dissertation.  Characterization of Q67H 
asymmetric mutants generated in the Quad 3 construct suggest that a shift in the 
equilibrium towards a single topology occurs in this construct as illustrated in Figure 8. 
Goal of Research Project 
The goal of this research project is to asymmetrically mutate R67 DHFR such that 
unique binding sites are provided to the substrate and cofactor.  By doing so, we propose 
to gain an understanding of the contacts occurring between residues located in specific 
domains of the active site and the ligands.  For this project, we have chosen to focus on 
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two active site residues, glutamine 67 and tyrosine 69, both of which are proposed to 
interact with both DHF and NADPH.    
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Abstract 
R67 dihydrofolate reductase (DHFR) is an R-plasmid encoded enzyme that 
confers resistance to the antibacterial agent, trimethoprim.  This homotetramer possesses 
a single active site pore and exact 222 symmetry.  The symmetry imposes constraints on 
the ability of the enzyme to optimize binding of the substrate, dihydrofolate (DHF), and 
the cofactor, NADPH, resulting in a “one site fits both ligands” approach.  This approach 
allows formation of either a NADPH•NADPH, a dihydrofolate•dihydrofolate or a 
NADPH •dihydrofolate complex.  The first two complexes are non-productive while the 
third is the productive catalytic species.  To break the symmetry of the active site, a 
tandem array of four R67 DHFR genes has been linked in frame, allowing individual 
manipulation of each gene copy.  Various numbers and combinations of asymmetric 
Q67H mutations have been engineered into the tandem gene array.  The Q67H mutation 
was chosen for investigation as it was previously found to tighten binding to both 
dihydrofolate and NADPH by ~ 100 fold in homotetrameric R67 DHFR (1).  Non-
additive effects on ligand binding are observed when 1 to 4 mutations are inserted, 
indicating either conformational changes in the protein or different cooperativity patterns 
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in the ligand•ligand interactions.  From steady state kinetics, addition of Q67H mutations 
does not drastically affect formation of the NADPH•dihydrofolate complex, however a 
large energy difference between the productive and non-productive complexes is no 
longer maintained.  A role for Q67 in discriminating between these various states is 
proposed.  Since theories of protein evolution suggest gene duplication followed by 
accumulation of mutations can lead to divergence of activity, this study is a first step 
towards asking if introduction of asymmetric mutations in the quadruplicated R67 DHFR 
gene can lead to optimization of ligand binding sites. 
Introduction 
Dihydrofolate reductase (DHFR)1 reduces dihydrofolate (DHF) to tetrahydro-
folate using the cofactor NADPH in a hydride transfer reaction.  Tetrahydrofolate is 
essential for cell survival as it is a precursor for formation of thymidylate, methionine, 
purine nucleosides, as well as other intermediates in metabolism.  The antibiotic 
trimethoprim has been used clinically as an inhibitor against E. coli chromosomal DHFR.  
However, R-plasmid encoded R67 DHFR confers resistance to this antibiotic.  This 
DHFR variant is not homologous either in genetic composition or structure to the 
chromosomally encoded enzyme (2,3). 
                                                 
1 Abbreviations:  DHFR, dihydrofolate reductase; wt, wild type; TMP, trimethoprim; DHF, 
dihydrofolate, NADP(+/H), nicotinamide adenine dinucleotide phosphate (oxidized/reduced); 
NMNH, reduced nicotinamide mononucleotide; MTH buffer, 50 mM MES + 100 mM Tris, + 
50 mM acetic acid polybuffer; ITC, isothermal titration calorimetry; CD, circular dichroism.  
Mutant enzymes containing amino acid substitutions are described by the wild type residue 
and numbered position in the sequence, followed by the amino acid substitution.  For 
example, Q67H R67 DHFR describes the gln67 → his mutant. 
 
 38
Numerous observations lead to the hypothesis that R67 DHFR is a primitive 
enzyme.  First, the active species is a homotetramer that possesses 222 symmetry as 
shown in Figure 1 (protein data bank file 1VIE, ref 3).  The single active site is a 25 Å 
pore that extends the length of the protein. As a consequence of the 222 symmetry, 
binding of DHF and NADPH to the pore results in formation of three different complexes 
(DHF•DHF, NADPH•NADPH or DHF•NADPH; ref 4).  Only the ternary complex 
(DHF•NADPH) results in catalysis.  For the latter complex, DHF occupies half the pore 
and cofactor the other half; the pteridine ring of DHF and the nicotinamide ring of 
NADPH encounter each other at the center of the pore where the reaction occurs (5).  A 
drawback of the 222 symmetry is that binding to NADPH and DHF cannot be 
independently optimized.  The enzyme appears to possess a binding “hot spot” that can 
accommodate (with some degree of overlap) both DHF and NADPH (6,7).   
A second observation suggesting R67 DHFR is a primitive enzyme is that 
mutations typically have a large cumulative effect since one mutation per gene results in 
four mutations per active site.  Mutations that tighten binding do not necessarily lead to 
enhanced catalytic efficiency as binding is concurrently tightened in all symmetry related 
sites.  This leads to substantial substrate and cofactor inhibition because of formation of 
the nonproductive complexes, DHF•DHF and NADPH•NADPH (1,4). 
A third observation is that R67 DHFR does not possess a general acid in its active 
site pore.  Instead it requires the substrate be activated by protonation (1,8-9).  In other 
words, catalysis increases as the pH approaches the pKa of N5 on DHF (2.59; ref 10). 
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Introduction of asymmetric mutations should break the constraints imposed on 
R67 DHFR due to its 222 symmetry, leading to addition of functional groups or building 
substrate specificity.  For the latter, mutations may be added to one half the pore leading 
to more specific binding of NADPH.  Conversely, specificity may be built in the other 
half of the pore, allowing more precise binding of DHF.  Construction of asymmetric 
mutations by mixing populations (e.g. wildtype and mutant R67 DHFRs) is limited by the 
pH dependent dissociation of tetrameric R67 DHFR into dimers (11).  Thus any 
heterotetramers formed and isolated will readily dissociate and reassociate to a mixture of 
homo- and heterotetramers upon titration of His62 and its symmetry related residues2 at 
pH values ≤8.   
To construct asymmetric mutations in R67 DHFR, a gene oligomerization 
strategy is necessary.  Therefore, Bradrick et al. (12) linked in-frame four copies of the 
gene coding for the 78 amino acid monomer.  The protein product of this tandem gene 
array is an active monomer with four times the mass of the wildtype (wt) monomer and 
that possesses the essential tertiary structure of the wt homotetramer.  The linker between 
gene copies corresponds to the natural N-terminus.  In this protein, residues are not 
numbered consecutively.  Instead residues 1-78 describe the 1st (A) domain, residues 101-
178 describe the 2nd (B) domain, residues 201-278, the 3rd (C) domain and residues 301-
378, the 4th (D) domain.  The domains correspond to the monomers in wt R67 DHFR. 
                                                 
2 The amino acids in the first monomer (A) are labeled 1-78; those in the second 
monomer (B), 101-178; those in the third monomer (C), 201-278; and those in the fourth 
monomer (D), 301-378.  For brevity, when a single residue is mentioned, all four 
symmetry related residues are implied.  The monomer arrangement going clockwise in 
the crystal structure 1VIF is ABDC (3).  To minimize confusion in the quadruplicated 
gene construct, we have re-labeled the monomers ABCD going clockwise.   
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This paper describes the addition of asymmetric mutations to the tandem gene 
array.  The Q67H substitution was initially chosen for analysis as it tightens binding to 
both NADPH and DHF in the context of the wt homotetramer (1).  Glutamine 67 and its 
symmetry related residues occur at the center of the active site pore.  They form the 
“ceiling” and “floor” of the pore (Figure 1).  Each Q67 residue hydrogen bonds with a 
symmetry related Q67 residue at both dimer-dimer interfaces.  Both of the hydrogen-
bonded pairs extend into the active site causing the pore radius to decrease near the 
middle.  From the folate co-crystal structure, Q67 forms extensive van der Waals 
interactions with the pteridine ring of folate (3).  Our recent computational docking 
studies using DOCK (docking based on van der Waals interactions) and SLIDE (docking 
based on hydrogen bond formation) predict interactions between Q67 and NMNH 
(reduced nicotinamide-ribose-Pi moiety of NADPH) (6).  In these predicted interactions, 
Q67 may form a hydrogen bond to one of the ribose OHs (O2′) through its NE2 group as 
well as form van der Waals interactions with several atoms of the nicotinamide ring 
through its sidechain.  This ternary complex model proposes that Q67 serves a dual role  
in binding both folate/DHF and NADPH.  The previously constructed Q67H mutant also 
supports this notion as it tightens binding to both NADPH and DHF by factors of 100 and  
6000 fold respectively (1).  Binding affinity may be strengthened due to ring stacking  
interactions between the imidazole ring of histidine and the nicotinamide and/or pteridine 
rings of NADPH and DHF respectively (13-15). 
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Figure 1.  Top left: the ribbon structure of homotetrameric R67 DHFR (1VIE in the 
protein data bank).  Each monomer is shaded differently and labeled A, B, C or D.  
While 1VIE assigns the monomer topology as ABDC going clockwise, we have 
revised this to ABCD to minimize confusion in the four gene copy construct. The 
single active site pore occurs in the center of the structure.  The Q67 sidechains are 
highlighted; they appear at the top and bottom surfaces of the active site pore.  Top 
right: An enlarged view of a pair of symmetry related Q67 residues from the B and C 
subunits.  The Q67s are in the center of the image in ball and stick format and the NE2 
and OE1 atoms labeled.  Water molecules are given as stars.  The active site pore is 
directly below the 2 glutamines.  The rest of the figure: a cartoon representing the 
topologies of various asymmetric Q67H mutations.  Quad 3 is the parent structure that 
possesses covalent linkers between each monomer in homotetrameric (wt) R67 DHFR.  
OE1 
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NE2 NE2
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D 
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Materials and Methods 
Site-directed mutagenesis 
A synthetic R67 DHFR gene, carried in pUC8, has been previously described 
(16).  A tandem array of 4 R67 DHFR genes was previously constructed where the genes 
are linked in-frame (12).  The resulting protein, named Quad 1, possesses four times the 
mass of the native R67 DHFR monomer.  Mutations were introduced using the PCR 
based protocol outlined in the Quickchange kit from Stratagene.  DNA sequencing was 
performed by the University of TN sequencing facility to confirm all constructs. 
Protein purification 
E. coli STBLII cells (F -mcrA ∆(mcrB-hsdRMS-mrr) recA1 endA1 gyrA96 thi 
supE44 relA1 λ -∆(lac-proAB); Gibco BRL) were used to maintain the tandem gene 
arrays as well as express the monomeric R67 DHFR and mutants (17).  Cells were grown 
at 30°C with shaking for approximately 60 hours.  The cells were lysed by sonication and 
the crude protein extract was clarified with streptomycin sulfate and concentrated with 
55% ammonium sulfate.  The proteins were purified using the following chromatography 
columns:  G-75 Sephadex size exclusion column, DEAE Fractogel column, Biorad 
HighQ column, and FPLC HighQ column (7,16).  The purity of the proteins was 
determined by SDS-PAGE.   
Isothermal titration calorimetry 
Binding affinities and the enthalpy associated with binding were monitored using 
isothermal titration calorimetry (ITC) as previously described (1,4).  Briefly, 
measurements were carried out on a Microcal Omega Ultrasensitive Isothermal Titration 
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Calorimeter equipped with a nanovoltmeter for improved sensitivity and connected to a 
circulating water bath for temperature control.  The data were automatically collected by 
an IBM PC running DSCITC data acquisition software and were analyzed using Origin 
version 2.9 software provided by the manufacturer.  The design and operation of this 
instrument have been described by Wiseman et al. (18).  Samples typically consisted of 
~90-100 µM protein in MTH buffer (50mM MES, 100mM Tris, 50mM acetic acid, and 
10mM β-mercaptoethanol), pH 8.  This buffer maintains constant ionic strength from pH 
4.5 to 9.5 (19).  Measurements were performed at 28oC.  Ligand concentrations in the 
syringe were typically 20 times the protein concentration.  Addition of ligand to buffer 
only was performed to allow baseline corrections.  Data describing NADPH or DHF 
binding were fit to an interacting sites model where the stoichiometry of ligand binding 
was set equal to two.  Data describing binding of NADP+ were fit to a single site model.  
Ternary complex data were obtained by titrating DHF into a 1:1 mixture of R67 
DHFR:NADP+ and were fit to a single site model.   
Steady state kinetics 
The kinetic behavior of each protein was monitored using a Perkin-Elmer λ3a 
spectrophotometer controlled by an IBM PS2 (20).  The data were collected using the 
program UVSL3.  Each experiment was conducted at 30°C in MTH buffer.  Four to five 
subsaturating concentrations of both DHF and NADPH were utilized to monitor activity.  
To calculate kcat and Km values for those variants displaying no to minimal substrate or 
cofactor inhibition, the data were fit globally to the nonlinear Michaelis-Menton equation 
describing bisubstrate kinetics using SAS v8.2 (21; Smiley et al., manuscript in 
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preparation).  These values agree with the more traditional data analysis approach (22, 
23) where primary linear 1/[substrate] vs 1/velocity plots are followed by secondary 
plots, yielding kinetic parameters.  To calculate kcat and Km values for those variants 
displaying substantial substrate/cofactor inhibition, the data were fit globally using SAS 
to a rate equation describing the R67 DHFR mechanism (4).  The mechanism is shown in 
Scheme I and the corresponding rate equation is: 
 kcat • [Etotal] • [DHF] • [NADPH] 
v =  --------------------------------------------------------------------------------   
{[DHF][NADPH] + Km (DHF) • [NADPH] + Km (DHF) • Kd1 (NADPH) +  
 
Km (NADPH) • [DHF] +  (Km (DHF) • [NADPH]2 / Kd2 (NADPH)) + (Km (NADPH) • [DHF]2/  
 
Kd2 (DHF))}         (1) 
 
where v is the velocity of the reaction; [Etotal], [DHF], [NADPH] are the concentrations of 
enzyme, substrate and cofactor; and Kd1 and Kd2 are the first and second binding  
constants for the specified ligands as measured by isothermal titration calorimetry (ITC). 
In fitting these data sets, the Kd values obtained by isothermal titration calorimetry were 
used as constraints.  Since three Kd values are entered explicitly with bounds allowing 
some minor variation, the fourth Kd is solved using a closed thermodynamic loop 
relationship (Km (NADPH) = Kd1 (NADPH) • Km (DHF) / Kd1 (DHF)).  To keep any variation from 
funnelling to the fourth Kd, a ratio of Kd1 (NADPH) to Kd1 (DHF) was sometimes used as a 
fixed parameter (again with bounds allowing some minor variation).  In the fitting 
process, the inputted Kd values and the Kd1 ratio were allowed to vary by 2-3 fold.  If the 
2-3 fold changes in Kd values gave better fits to the steady state kinetic data, then these 
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Scheme 1.  Binding scheme for R67 DHFR proposed from steady-state kinetics (16) 
and isothermal titration calorimetry (4) studies. 
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Kd values were used to re-assess the ITC fits.  All ITC refits remained within 90% 
confidence intervals. 
Protein and ligand concentrations were determined spectrophotometrically.  For 
all mutants, extinction coefficients were determined using the biuret assay (24).  Ligand 
concentrations were determined using the following extinction coefficients: 28,000 
l/mol•cm at 282 nm for DHF (25) and 6230 l/mol•cm at 340 nm for NADPH (26).  The 
molar extinction coefficient used to assess DHFR reduction of DHF was 12,300 l mol-
1cm-1 (27). 
Results 
Construction of an altered tandem array 
Direct mutagenesis of the quadruplicated gene construct described in Bradrick et 
al. (12) did not allow control of either the number of mutations or their placement since 
each of the gene copies was identical.  Therefore a different mutagenesis strategy was 
devised.   In this alternate approach, unique restriction sites were designed between the 
gene copies by mutagenesis of the 5′ and 3′ ends of each of the single copy genes.  This 
process resulted in 4 different single R67 DHFR gene constructs.  Introduction of an 
asymmetric mutation into the desired gene copy was next performed and ligation of the 
resulting constructs allowed reconstruction of the quadruplicated gene containing the 
desired asymmetric mutation(s).   
The tandem array containing the restriction sites but no asymmetric mutations is 
named Quad 2.  Figure 2 shows a Bcl1 site at the 5′ end of gene copy 1; an EcoRV site 
separates gene copies 1 and 2; a KpnI site occurs between copies 2 and 3; an ApaI site 
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Figure 2.  Flowchart for construction of the quadruplicated R67 DHFR genes.  The 
complete R67 DHFR gene sequence is given in reference 16. Construction of the initial 
quadruplicated gene, Quad 1, is described in reference 12.  Each gene copy coding for a 
78 amino acid monomer is denoted by a horizontal arrow.  Partial DNA sequences with 
engineered unique restriction sites (in bold) are shown below the line while the 
corresponding amino acids are given above the line.  For Quad 3, two additional 
mutations were added; gene copy 1 contains a S59A mutation while gene copy 4 
contains a H362L mutation (29). 
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Bcl EcoRKpnI  ApaIEcoR
N. I277R-N278A-M301L…..H362………. S59…Start M1……………... ….I77-N78D-M101I… I177R-N178Y-M201L… 378 end 
Quad 3 
NH362L……378 end  SStart M1………...... 59A…..... I77-N78D-M101I.... I177R-N178Y-M201L…. I277R-N278A-M3011L..
AA AGG-GCC-CTG….…..CTC…. C-TAA-TAG-AATG-ATC-AAG….GCT.... TC-GAT-ATC……..      AGG-TAC-CTC………
EcoR KpnI  Bcl EcoRApaI
AATG-ATC-AAG…TCT…… TC-GAT-ATC…….AGG-TAC-CTC……….AGG-GCC-CTG……CAC.. AAC-TAA-TAG-
 
Quad 2 
GENE COPY GENE COPY GENE COPY GENE COPY 
Quad 1 
EcoR
 77-N78-M101…….   I177-N178-M201….  Start M1………..….   N378 endI277-N278-M301……H362…..
   
IS59……….  
Bcl
 AATG-ATC-AAG…TCT………TC-AAC-ATG………ATC-AAC-ATG…..
 ATC-AAC-ATG…….CAC… AAC-TAA-TAG- 
divides genes copies 3 and 4; and an EcoR1 site is positioned at the 3′ end of gene copy 
4.  Introduction of the restriction sites in the gene creates several amino acid changes.  
The C-terminal wt R67 DHFR sequence is Ile77-Asn78; for direct connection to the 
second gene copy, the next residue would be Met101.  However for the construct that 
contains the EcoRV site, N78D+M101I mutations are present.  For the construct that 
introduces the KpnI site, I177R+N178Y+M201L mutations occur.  Lastly, for the Apa I 
restriction site, I277R+N278A+M301L mutations are introduced.  While these changes 
are not always conservative, a comparison of type II DHFR sequences indicates the N-
terminal 26 residues and the C-terminal 2 residues are not well conserved (28).  Further, 
removal of the N-terminal 16 amino acids by chymotrypsin treatment does not affect 
enzyme activity (16). 
From an examination of the homotetramer structure, it appears feasible to form 
either an ABCD or an ABDC topology or a mixture of the two species in the 
quadruplicated gene product.  This option arises as the N-terminal Pro19 residues from 
the C and D monomers are equidistant (>45Å) from the C-terminal N78 residue in the B 
monomer in the R67 DHFR crystal structure.  These two symmetry related Pro19 
residues are ~15 Å apart3. To constrain the various potential folding topologies to a single 
ABCD domain arrangement, we introduced a S59A mutation in gene copy 1 and a 
H362L mutation into gene copy 4.    Individually, the S59A and H62L mutations 
destabilize the homotetramer, forming inactive dimers.  However 1:1 mixtures restore 
almost full activity, indicating they complement each other and form heterotetramers 
                                                 
3 The N-terminal 17-18 amino acids are disordered in the dimer structure (30) and when 
16 N-terminal amino acids were cleaved off, the truncated protein crystallized as a 
tetramer (3). 
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(29).  The quadruple variant containing these mutations is named Quad 3.  All subsequent 
mutants described below use this as a “parent”. 
The final step in this process introduced Q67H mutations into Quad 3.  A single 
Q67H mutation was constructed in gene copy 1; single mutations in other gene copies 
were not constructed as the 222 symmetry of R67 DHFR predicts they will be equivalent.  
For double Q67H mutants, 3 non-equivalent constructs are possible.  The first contains 
mutations in gene copies 1&2 (=Q67H:1+2); the second contains Q67H mutations in 
gene copies 1&3 (= Q67H:1+3); and the third contains Q67H mutations in gene copies 
1&4 (=Q67H:1+4).  In the 1+2 construct, Q67H lies next to a wt Q67 residue at the 
“floor” as well as the “ceiling” of the pore and the mutations occur on the “left hand” side 
of the pore.  In the 1+3 construct, Q67H again lies next to a wt Q67 residue at the “floor” 
of the pore, however the second Q67H mutation occurs “diagonally” across the pore on 
the “ceiling.”  In the Q67H:1+4 construct, a Q67H pair should form at the “floor” of the 
active site pore while a wt Q67 pair should occur at the “ceiling”.  From the symmetry, 
the 1+2 construct should be equivalent to a 3+4 construct; the 1+3 and 2+4 constructs 
should be equivalent as are the 1+4 and 2+3 constructs. Only one triple mutant, 
Q67H:1+2+3, was constructed as was a single quadruple mutant, Q67H:1+2+3+4.  
Figure 1 shows a cartoon of the mutant configurations. 
Does the Quad 3 protein mimic WT R67 DHFR? 
Prior to construction and evaluation of any asymmetric mutants, it was necessary 
to assess the effect of the mutations that added the unique restriction sites between gene 
copies, as well as the S59A and H362L mutations used to constrain possible folding 
topologies to the quadruplicated gene product.  To determine whether the Quad 3 protein 
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mimics wt R67 DHFR, steady state kinetics and isothermal titration calorimetry were 
utilized.  Table 1 gives the kcat and Km values for wt R67 DHFR, the original Quad 1 
protein (12) as well as the Quad 3 protein derived from this work.  The kcat and Km values 
for Quad 3 are similar to those of Quad 1 and are within a factor of 2 of wt R67 DHFR, 
indicating the effects of the mutations are minor. 
A comparison of ITC binding data for NADPH, DHF and NADP+ is given in 
Table 2.  Again, the Quad 3 protein mimics wt R67 DHFR reasonably well.  The largest 
difference is an approximately 5 fold weaker binding of the first DHF molecule.  
However the previously reported Kd values for DHF binding to wt DH→sFR were fit 
including the first data point (4).  In contrast, the values reported in this study do not use 
the first data point due to its variability associated with the first mixing event in the 
calorimeter.  This difference in fitting explains an approximately 2 fold change in Kd.  
Any additional variance arises from differences between the Quad 3 and wild type 
proteins. 
What are the effects of the asymmetric Q67H mutations? 
 To assess the effects of the Q67H mutations on ligand binding, ITC was used to 
monitor binding to DHF, NADPH, and NADP+ in various combinations.  A 
representative titration is given in Figure 3.  Data for all mutants were obtained except for 
the Q67H:1+2+3+4 variant.   We find the data for this species are not readily 
reproducible as the protein solution often is turbid after the titration, indicating 
aggregation at high protein concentrations.   
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Table 1.   A comparison of steady state kinetic values at pH 7.0 for numerous R67    
DHFR constructs. 
 
Enzyme Variant kcat (sec-1) Km (NADPH) (µM) Km (DHF) 
(µM) 
R2 
(SAS) 
WT R67 DHFRa 1.3 3.0 5.8 - 
Quad 1b 0.75 4.5 8.0 - 
Quad 3c 0.81 ± 0.02 4.4 ± 0.4 6.7 ± 0.4 90% 
Q67H:1c 0.23 ± 0.01 1.3 ± 0.1 3.6 ± 0.2 90% 
Q67H:1+2d 0.21 ± 0.01 0.28 ± 0.02 3.6 ± 0.3 89% 
Q67H:1+3 d 0.23 ± 0.01 1.8 ± 0.1 11 ± 0.6  97% 
Q67H:1+4 d 0.15 ± 0.01 0.95 ± 0.14 2.6 ± 0.5  84% 
Q67H:1+2+3d 0.090 ± 0.01 0.45 ± 0.06 7.5 ± 2.3  
 
85% 
Q67H:1+2+3+4d 0.10  ± 0.01 0.026 ± 0.004 0.13 ± 0.02 
 
86% 
Q67H R67 DHFR 
(pH 8) e 
Q67H R67 DHFR  
(pH 8) f 
0.022 ± 0.001  
0.025 ± 0.001 
0.03 (calculated) 
0.014 ± 0.002 
0.16 ± 0.005  
0.14 ± 0.01 
- 
91% 
  a  Values from reference 16. 
   b  Values from reference 12. 
   c  Global non-linear fit to the Michaelis-Menton equation describing bisubstrate kinetics  
      using SAS. 
   d  Global non-linear fit (SAS) to a rate equation describing the R67 DHFR mechanism  
      (eq 1) using ITC values as constraints. 
   e  Fit values from reference 1 using FITSIM. 
   f  Global non-linear fit (SAS) to a rate equation describing the R67 DHFR mechanism  
      (eq 1) using ITC values as constraints. 
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Table 2.  A comparison of wt R67 DHFR with Quad 3 using isothermal titration 
calorimetry to monitor ligand binding. 
 
Complex Kd (µM) ∆H (cal/mol) Stoichiometry 
Wt R67 DHFR with 
NADPHa 
5.0 ± 0.3 
48 ± 2 
-8600 ± 200 
-5800 ± 2500 
1.56 ± 0.14 
Quad 3 with NADPH 4.0 ± 0.3 
37.1 ± 3.0 
-3000 ± 26 
-9400 ± 83 
2b 
Wt R67 DHFR with 
DHFa 
250 ± 50 
4.4 ± 0.7 
-7900 ± 900 
-1400 ± 60 
1.88 ± 0.1 
Quad 3 with DHF 46 ± 0.7 
2.0 ± 0.02 
-8420 ± 110 
-3750 ± 39 
2b 
Wt R67 DHFR with 
NADP+a 
99 ± 3 -7700 ± 500 0.99 ± 0.03 
Quad 3 with NADP+ 31.3 ± 1.3 -7000 ± 450 0.95 ± 0.02 
Wt R67 DHFR • NADP+ 
with DHFa 
4.8 ± 1.0 -11700 ± 300 1.22 ± 0.01 
Quad 3 • NADP+ with 
DHF 
4.9 ± 0.1 -11500 ± 800 0.99 ± 0.01 
        a  Results from reference 12.  Microscopic values (kd1, kd2) are reported.  The 
        statistical relationship between microscopic and macroscopic constants is Kd1 = ½ 
        kd1 and Kd2 = 2 kd2 (52). 
      b  The stoichiometry is set at 2 by choosing the two interacting sites model in Origin,     
        the software used by the ITC for fitting the data.  Since the value is set, it is  
        presented with no error.  
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Figure 3.  Isothermal titration calorimetry analysis of DHF binding to Q67H:1+4 
DHFR.  The protein concentration was 100 µM and the data were fit using the 2 
interacting sites model (dotted line).  Best fit values are given in Table 4.  To fit 
the steady state kinetic data (table 1), the ITC values were allowed to vary up to 3 
fold from the best fit values.  In fitting of the kinetic data, the (microscopic) Kd 
values for DHF binding to Q67H:1+4 shifted to Kd1 = 2.12 and Kd2 =106 µM.  
These involve a 2.3 fold increase and a 3 fold decrease from the Kd values given in 
Table 4.  The refit is shown by the solid line.   
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Table 3 gives the Kd and ∆H values associated with binding of NADP+.  Only one 
NADP+ binds per R67 DHFR as compared to 2 NADPH molecules.  This different 
stoichiometry is likely due to charge-charge repulsion between the positively charged 
nicotinamide rings in NADP+.  A trend noted is introduction of each successive Q67H 
mutation results in tighter binding of NADP+ over a 7-fold range (with some variability 
for the different topologies of the double mutants).  A generally linear relationship 
between the number of mutations and the Kd is consistent with no conformational 
changes upon binding and additive (independent) interactions between the Q67H residues 
(30).  While a model does not exist for bound NADP+, a model for bound, reduced NMN 
has recently been generated by docking NMNH into R67 DHFR•FolI, where Fol1 is the 
productively bound pteridine ring in the crystal structure (6).  In this model, the reduced 
nicotinamide moiety of NMN interacts with one pair of symmetry related Q67 residues, 
while the pteridine ring of FolI interacts with the other pair of Q67 residues.  One 
interpretation of the above ITC results suggests that bound NADP+ interacts with at least 
three of the Q67 residues since successive addition of up to 3 mutations continues to 
tighten binding.  This scenario would require NADP+ to bridge between both pairs of 
Q67 residues, a distance of ~11A (between carboxamide atoms).  This interpretation 
suggests some alteration of the binding mode for NADP+ with respect to that proposed 
for reduced NMN in a ternary complex.  An alternate hypothesis is that when NADP+ 
binds to either wt or Q67H R67 DHFRs, the binding constant reflects the statistical 
average of binding at each symmetry related site.  Since the sites are equivalent in the 
homotetramer, statistical averaging has no effect.  However when NADP+ binds to an
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Table 3.  Binding of NADP+ to the various DHFR species as monitored by ITC at pH  
8.0. 
 
Complex Kd (µM) ∆H (cal/mol) stoichiometry 
Quad 3 titrated with 
NADP+ 
31.3 ± 1.3 -7000 ± 450 0.95 ± 0.02 
Q67H:1 with NADP+ 19.3 ± 1.9 -6500 ± 250 1.1 ± 0.03 
Q67H:1+2 with NADP+ 13.1 ± 1.0 -7600 ± 240 1.1 ± 0.02 
Q67H:1+3 with NADP+ 15.3 ± 1.4 -6300 ± 340 1.1 ± 0.01 
Q67H:1+4 with NADP+ 11.2 ± 1.0  -13,900 ± 520 1.0 ± 0.04 
Q67H:1+2+3 with 
NADP+ 
4.23 ± 0.3  -12,200 ± 220 1.1 ± 0.05 
Q67H R67 DHFR with 
NADP+a     
3.4 ± 0.9 -9900 ± 500 0.70 ± 0.05 
       a  Results from reference 1.
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asymmetric mutant, for example Q67H:1, there are several possible binding orientations, 
i.e. one symmetry pair of orientations would place the nicotinamide ring near a wt Q167-
Q267 homo-pair while a second pair of orientations would juxtapose the nicotinamide 
ring near the Q67H-Q367 hetero-pair.  If the contribution of the Q67H residue to the 
overall binding constant is minor, the observed Kd may be an average value reflecting the 
contributions associated with binding at non-equivalent sites.  As the number of Q67H 
mutations increases, this would lead to an overall decrease in the apparent Kd.  This 
explanation seems more likely than the model where NADP+ interacts with ≥ 3 Q67H 
residues, although that cannot be ruled out.   
A more complex relationship arises when the effects of the Q67H mutations on 
binding NADPH or DHF (binary conditions) are assessed.  Table 4 gives the Kd and ∆H  
values observed.  Several observations are apparent.  First, for DHF binding, the addition 
of 1 Q67H mutation has a large, immediate effect on the first Kd value, while for NADPH 
binding, it takes 3 mutations to show any advance towards the tighter binding previously 
observed in the Q67H homotetramer (1).  Second, the various double mutants show 
different binding patterns, particularly for DHF, indicating they present different 
arrangements of the Q67H mutations.  This implies that the Quad 3 parent protein has 
been locked into a single topology (ABCD) and that the effect of two Q67H mutations is 
a function of how they are arranged with respect to each other.  Third, the cooperativity 
between ligands (monitored by Kd2 / Kd1) shows large variations, particularly for binding 
of DHF.  These issues are discussed more fully below. 
 Since NADP+ binding gets progressively tighter with the successive addition of 
Q67H mutations, a straightforward result for binding of NADPH would have been a  
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Table 4.  Results of binding studies at pH 8.0 using isothermal titration calorimetry.  
Complex Kd (µM) ∆H (cal/mol) Kd2 / Kd1 
Quad 3 with NADPH 4.0 ± 0.3 
37.1 ± 3.0 
-3000 ± 26 
-9400 ± 83 
9.3 
Q67H:1 with NADPH 3.6 ± 0.8 
53.5 ± 6.5 
-5800 ± 95 
-9830 ± 160 
15 
Q67H:1+2 with NADPH 2.7 ± 0.1 
15.0 ± 0.4 
-5030 ± 28 
-3530 ± 32 
5.6 
Q67H:1+3 with NADPH 8.7 ± 0.5 
51.1 ± 3.2 
-8650 ± 59 
-5030 ± 91 
5.9 
Q67H:1+4 with NADPH 17.7 ± 0.8 
16.1 ± 0.5 
-8540 ± 100 
-14,000 ± 165 
0.91 
Q67H:1+2+3 with 
NADPH 
0.21 ± 0.01 
3.5 ± 0.07 
-3740 ± 20 
-2900 ± 75 
17 
Q67H R67 DHFR with 
NADPHa 
0.054 ± 0.016  
0.31 ± 0.06 
-4800 ± 100 
-2500 ± 400 
5.7 
Quad 3 with DHF 46 ± 0.7 
2.0 ± 0.02 
-8420 ± 110 
-3750 ± 39 
0.043 
Q67H:1 with DHF 0.88 ± 0.06 
2.0 ± 0.05 
-6340 ± 46 
-5770 ± 74 
2.3 
Q67H:1+2 with DHF 0.97 ± 0.04 
1.1 ± 0.02 
-6250 ± 44 
-5740 ± 45 
1.1 
Q67H:1+3 with DHF 1.5 ± 0.05 
20 ± 0.6 
-8500 ± 260 
-1100 ± 33 
13 
Q67H:1+4 with DHF 0.93 ± 0.03 
320 ± 16 
-7340 ± 31 
-3360 ± 23 
340 
Q67H:1+2+3 with DHF 0.21 ± 0.1 
0.64 ± 0.1 
-7350 ± 76 
-7270 ± 82 
3.0 
Q67H R67 DHFR with 
DHFa 
0.040 ± 0.008 -8000 ± 100 identical 
sites 
              a  Results from reference 1. 
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similar trend.  Instead, addition of 1 Q67H mutation has a minimal effect on NADPH 
binding.  Addition of two mutations has observable effects on binding, particularly for 
the Q67H:1+4 configuration, but tight binding is not observed.  Only when three Q67H 
mutations are introduced does tighter binding begin to appear.  While we would expect 
the Q67H:1+2+3+4 mutant to mimic the Q67H homotetramer and display 100 fold lower 
Kd values, we are unable to confirm this prediction due to protein aggregation.   
The non-linearity between the number of Q67H mutations and the corresponding 
 NADPH Kd values suggests conformational changes may occur.  These changes could 
describe altered interactions between either the wild type Q67 and mutant Q67H residues 
and/or between the 2 ligands. The first alternative appears feasible as the Q67 residues 
occur very near the 222 symmetry operator and each Q67 residue interacts with its 
symmetry related partner.  Therefore it would not be surprising if introduction of a Q67H 
mutation alters the position of the other member of the pair.  Another possibility to 
explain the binding data is that the cooperativity between the 2 NADPH molecules is 
altered. One measure of the interligand cooperativity is given by the ratio of Kd2/Kd1.  As 
seen in Table 4, this ratio varies from a low of 0.91 to a high of 17 depending on the 
number of mutations introduced as well as the positioning of the double mutants.  We 
previously observed that this ratio varies less than 2 fold when studying NADPH binding 
to various homotetrameric R67 DHFR mutants (Q67H, I68L, Y69F; refs 1,7). This 
minimal variance of the Kd2 to Kd1 ratio was striking as the Kd values themselves varied 
over 3 orders of magnitude!  From those studies, we concluded that interligand 
cooperativity is important in binding and catalysis in R67 DHFR and must be linked to 
the symmetry of the active site pore.  Therefore the data given in Table 4 are the first 
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examples of varying levels of cooperativity associated with NADPH binding to R67 
DHFR.  We also find support for interligand cooperativity modulating the nonlinear 
effects of the asymmetric Q67H mutations on NADPH binding as the transition from a 
relatively linear relationship between the number of mutations and log Kd to a clearly 
non-linear relationship occurs as the binding stoichiometry goes from one (NADP+) to 
two (NADPH).  This difference suggests the conformational changes could also arise 
from ligand-ligand interactions.  The main differences between NADP+ and NADPH are 
the positive charge and aromaticity of the nicotinamide ring in NADP+. 
 In contrast to the above results with NADPH, binding of DHF shows a clear 
effect upon addition of one Q67H mutation.  Binding is tightened to the first DHF 
molecule by a factor of 52, suggesting a direct interaction between the Q67H mutation 
and DHF.  The second Kd is also tight.  Since the remaining residues are wt, this result 
suggests positive cooperativity remains between the two DHF molecules.  Addition of 2 
mutations shows varying results, depending on the configuration of the Q67H residues.  
For the Q67H:1+2 double mutant, both Kd values are relatively tight, suggesting either 
that each DHF is responding to the presence of the Q67H and Q167H mutations at the 
“floor and ceiling” of the pore, or that positive cooperativity remains between the two 
DHF molecules.  For the Q67H:1+3 and Q67H:1+4 double mutants, positive 
cooperativity between the DHF molecules clearly does not occur and 2 possibilities can 
be envisioned to explain the binding pattern.  Either the two DHF molecules now bind 
differently enough so that negative cooperativity occurs between them or binding of the 
first DHF molecule is tight due to the presence of the Q67H mutations while binding of 
the second DHF molecule remains weak due to the interactions with the wt Q67 residues.  
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For the latter, minimal to no DHF-DHF interactions would be expected.  Alternatively, 
conformational changes associated with the mutations may be occurring as the Kds for 
the Q67H:1 mutant are different from the Q67H:1+4 mutant.  In these mutants, either 1 
or 2 mutations occur at one interface while the other interface possesses only wt residues.  
If the second DHF binding event was responding only to the wt Q167-Q267 residues, 
then similar values would be expected for these Kds.  This is not observed.  Finally, the 
introduction of 3 Q67H mutations also tightens binding to both DHF sites, although the 
effect is not as dramatic as for NADPH binding.  That 3 mutations can continue to affect 
the first Kd also supports a model where conformational changes are occurring, either via 
altered interactions between the wild type Q67 and mutant Q67H residues and/or between 
the 2 ligands.  The latter model where ligand-ligand interactions influence the binding 
behavior remains feasible, as positive cooperativity between DHF molecules is observed 
in Quad 3 while no to negative cooperativity patterns are detected for the various Q67H 
asymmetric mutants.  
 Addition of DHF to R67 DHFR•NADP+ to form a ternary complex was 
additionally monitored by ITC methods.  The Kd values are given in Table 5.  Only minor 
variations are observed, indicating the affinity of DHF for R67 DHFR•NADP+ remains 
fairly constant throughout this series.  To monitor interligand cooperativity between DHF 
and NADP+, we have continued to use a ratio of the Kd for the second binding event 
divided by the Kd for the first binding event.  In this case, the ratio is the Kd of DHF 
binding to R67 DHFR•NADP+ divided by the Kd for NADP+ binding to R67 DHFR.  The 
cooperativity values remain mostly constant and indicate positive cooperativity between  
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Table 5.  Ternary complex formation monitored by ITC. 
 
Complex Kd (µM) ∆H (cal/mol) stoichiometry Kd (DHF ternary)/ 
Kd (NADP+ binary) 
 
Quad 3 • NADP+ 
with DHF 
4.9 ± 0.1 -11500 ± 800 0.99 ± 0.01 0.16 
Q67H:1 • NADP+ 
with DHF 
2.2 ± 0.05 -11400 ± 940 1.0 ± 0.01 0.11 
Q67H:1+2 • NADP+ 
with DHF 
4.5 ± 0.1 -9400 ± 400 0.94 ± 0.01 0.34 
Q67H:1+3 • NADP+ 
with DHF 
4.8 ± 0.1 -9400 ± 600 1.07 ± 0.01 0.31 
Q67H:1+4 • NADP+ 
with DHF 
2.0 ± 0.05 -10000 ± 370 1.03 ± 0.01 0.18 
Q67H:1+2+3 • 
NADP+ with DHF 
6.6 ± 0.2 -8500 ± 590 1.01 ± 0.03 1.6 
Q67H R67 DHFR • 
NADP+ with DHFa 
6.7 ± 0.3 -9000 ± 450 0.82 ± 0.04 2.0 
     a  Results from reference 1. 
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the ligands, except for the Q67H:1+2+3 mutant, which indicates negligible or a slight 
negative cooperativity.  
Steady state kinetics of asymmetric mutants 
The asymmetric mutants were additionally evaluated by steady state kinetic analysis.  
The values were readily determined for Q67H:1 using SAS to globally fit all the data to 
the Michaelis Menton equation describing bisubstrate kinetics.  The data and a 3D 
representation of the fit are shown in Figure 4a; best fit values are given in Table 1.  Each 
grid line on the 3D plot corresponds to a constant first ligand concentration with varying 
second ligand concentrations (and vice versa).  The Km values both decrease ~1.5 fold 
and kcat decreases 3 fold.  These values agree with those determined by data linearization, 
followed by secondary replots (22, 23).   
Analysis of the kinetic data for the other mutants is less straightforward as they  
display various levels of substrate and cofactor inhibition.  Therefore a rate equation (eq 
1) was derived for the mechanism describing inhibition associated with formation of the 
2 non-productive complexes, NADPH•NADPH or DHF•DHF (4).  The steady state 
kinetic data were then fit globally using SAS; the Kd values obtained by ITC were 
entered as constraints.  Since the mechanism predicts formation of the NADPH•NADPH 
or DHF•DHF complexes as well as the productive NADPH•DHF complex, this fitting 
method requires data to cover a wide range of substrate/cofactor “space” describing 
catalysis as well as inhibition.  Therefore >130 but <370 data points were used in these 
fits. 
 64
Figure 4.  Steady state kinetic data for various R67 DHFRs.  Panel A describes the 
Q67H:1 R67 DHFR, which was fit to the Michaelis-Menton equation describing 
bisubstrate kinetics using SAS.  Data points above and below the calculated 3D plot 
are filled and hollow stars respectively.  Panel B describes the Q67H homotetramer 
data (Park et al., 1997a). This representation reverses the axes for [DHF] and 
[NADPH] to accentuate a “ridgeline” of maximal activity.  Nonlinear fitting was 
performed by SAS to equation 1 and Table 1 gives the best fit values.  Kd values 
derived from ITC data were used as constraints in fitting with 2-3 fold variations 
accepted if the ITC data could be reasonably refit with these values.  Panel C 
describes the Q67H:1+2 data as well as its accompanying 3D fit.  The plots for the 
Q67H:1+3 and Q67H:1+4 double mutants are given as supplementary information in 
the appendix. 
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 Since global nonlinear SAS analysis of steady state kinetic data to a complicated 
rate equation is a new approach, we first confirmed its ability to fit the Q67H 
homotetramer data that had previously been analyzed with the computer program, 
FITSIM (1,31).  Our FITSIM analysis at that time indicated the Q67H homotetramer data 
could not be fit well without varying the ITC Kd values 2-3 fold.  These alterations arose 
as NADPH was observed to be more inhibitory than DHF, even though the Kd values 
were similar.  To fit the kinetic data, both NADPH Kd values were decreased 3 fold and 
both DHF Kd values were increased 2 fold.  In this scenario, NADPH binds more tightly 
than DHF, providing more inhibition.  SAS was able to identify this solution.  In 
addition, SAS identified a second possibility where the cooperativity patterns were 
altered.  In this solution, neither Kd1 for NADPH or DHF were altered, but reduced 
negative cooperativity was proposed between the two NADPH molecules as well as the 
introduction of negative cooperativity between the two DHF molecules.  In this second 
model, the NADPH•NADPH complex forms more easily than expected as its Kd values 
are closer, while it is harder to form the DHF•DHF complex as its Kd values are farther 
apart.  A comparison of the correlation coefficient (R2) for these 2 different fits supports 
the first SAS solution.  Figure 4b shows the data overlaid on a 3D representation of the fit 
for the Q67H homotetramer.  A good fit is observed with a R2 value of 91%; best fit 
values are given in Table 1.  This analysis clearly validates the SAS global fitting 
approach.  
Analysis of the steady state kinetic data for the other asymmetric mutants was 
therefore performed using SAS.  The data set for the Q67H:1+2 mutant as well as a 3D 
representation of the fit are given in Figure 4c.  The data and 3D plots show 
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substrate/cofactor inhibition at low second ligand concentrations.  The fit values for this 
asymmetric mutant as well as the others are given in Table 1. 
Each double mutant displays different kinetic behavior, indicating the various 
topologies generate different responses. The Q67H:1+2 double mutant displays obvious 
cofactor inhibition, its kcat value decreases ~3 fold and Km values decrease ~16 and 2 fold 
for NADPH and DHF respectively, leading to a 4 fold increase in kcat/Km (NADPH).  The 
next double mutant, Q67H:1+3, exhibits cofactor and substrate inhibition (particularly at 
low second ligand concentration) as well as a ~4 fold decrease in kcat, a 2.5 fold decrease 
in Km (NADPH)  and a slight (1.6 fold) increase in Km (DHF).  The Q67H:1+4 double mutant 
displays no obvious substrate or cofactor inhibition and is readily saturated.  While kcat 
decreases ~6 fold, Km (NADPH) decreases 5 fold, yielding an approximately equal kcat/Km 
(NADPH) value to that of Quad 3.  Km (DHF) decreases approximately 3 fold.  The Q67H:1+2 
double mutant is the most functional with respect to kcat/Km (NADPH) values while the 
Q67H:1+4 double mutant maintains its catalytic efficiency with no obvious 
substrate/cofactor inhibition.  In fact, a fit of the Q67H:1+4 data to the bisubstrate 
kinetics equation provides very similar fit values. 
The triple mutant shows more obvious NADPH and DHF inhibition, and the 
corresponding fit indicates a further decrease in kcat, and Km values that remain within the 
range of the double mutants.  The quadruple mutant displays increasing levels of NADPH 
and DHF inhibition, similar to that of the Q67H homotetramer (1).  The data set for the 
Q67H:1+2+3+4 mutant was fit using the ITC Kd values measured for the Q67H 
homotetramer as constraints; the values were allowed to deviate up to 4 fold (within 
range of the Q67H:1+2+3 mutant).  For the quadruple mutant, kcat decreases 8 fold with 
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respect to Quad 3, while Km (NADPH) decreases 170 fold and Km (DHF) decreases 48 fold.  
This leads to a 21 fold increase in kcat / Km (NADPH) which is accompanied by tighter 
binding of NADPH and DHF at symmetry related sites, resulting in severe 
cofactor/substrate inhibition.  The similarity between kinetic values suggests the 
Q67H:1+2+3+4 quadruple mutant mimics the Q67H homotetramer reasonably well.  
To deal with fitting the kinetic data, SAS varied the Kd constraints by various 
combinations of 2 approaches: by either maintaining the cooperativity but changing the 
overall Kd values 2-3 fold (the Q67H:1+2+3, Q67H:1+2+3+4 and Q67H homotetramer 
data sets) and/or by altering the cooperativity between ligands.  For example, in the 
Q67H:1+2 data set, negative cooperativity between NADPH molecules was weakened (8 
fold) while negative cooperativity between the two DHF molecules was enhanced (2 
fold).  For the Q67H:1+3 data set, cooperativity between NADPH molecules was 
maintained while binding was strengthened (3 fold), but the negative cooperativity  
between DHF molecules was enhanced (6 fold).  For the Q67H:1+4 data set, negative 
cooperativity was enhanced between NADPH molecules (9 fold, ie a 3 fold tighter 
binding of the first NADPH and a 3 fold weaker binding of the second NADPH), while 
negative cooperativity was weakened between DHF molecules (7 fold).  To fit the kinetic 
data with reasonable R2 values required changes in the ITC constraints.  Two to three fold 
changes in Kd values were tolerated by the ITC refits reasonably well.   
Effects of the mutations on protein structure 
To confirm that all the Quad 3 protein variants are monomeric, gel filtration 
studies were performed to assess how the oligomeric state varies as a function of pH.  All 
measurements confirm the protein is a monomer at both pHs 5 and 8 (data not shown).  
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We further assessed the level of structural change by monitoring the equilibrium between 
“closed” and “open” forms of the quadruplicated gene product (which correspond to the 
tetrameric and dimeric forms in wt R67 DHFR) using protein fluorescence.  This titration 
monitors the pKa of the symmetry related H62 residues (of which 3 remain in Quad 3 as 
it contains a complementing S59A and H362L pair) by the fluorescence of nearby W38 
residues (11,12).  The behavior of Quad 3 continues to mimic that of Quad 1 while the 
Q67H mutations slightly destabilize the “closed” structure (see Figure 8 and Table 6 in 
the appendix).  All proteins are in the active (“closed”) form for activity measurements at 
pH 7 and ITC measurements at pH 8. 
Since the non-additive nature of the kinetic and binding data suggest either a 
conformational change in the protein or alterations in the ligand-ligand interactions, we 
assessed the effect of the mutations on protein structure by CD measurements.   There is 
some variation in the CD signal (not shown).  The largest change is observed in the 
Q67H:1+2+3+4 mutant, however this signal change correlates with that previously seen 
for the Q67H homotetramer (1).  While these spectral changes may reflect some degree 
of conformational change, they also could arise from the proximity of the Q67H mutation 
to W38 (~3.7-4A), as Woody (32) indicates aromatic side changes can make detectable 
contributions to the far-UV CD signal.   
Discussion 
The Q67H homotetramer has been observed to bind both NADPH and DHF more 
tightly (>100 fold) than wild type R67 DHFR (1).  Linked to this behavior was a 6.8 fold 
decrease in kcat, resulting in a 3.6 fold enhancement in kcat/Km (NADPH).  However the 
ability of the Q67H mutant to reach its transition state was compromised by tighter 
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binding of a second identical ligand at a symmetry related site, leading to substantial 
cofactor and substrate inhibition.  Therefore the symmetry in the active site pore imposes 
a balance between catalysis and inhibition.  Introduction of asymmetric mutations was 
pursued to determine if tight binding of the transition state could be uncoupled from 
inhibition. We reasoned if addition of 1-2 mutations was sufficient to tighten binding at 
one binding surface, the remaining wildtype residues at the other binding surface might 
not invoke tight binding and inhibition could be blocked.  We address these linked issues 
by discussing the interligand cooperativities as measured by ITC, followed by steady 
state kinetic analysis. 
What is the role of interligand cooperativity in R67 DHFR? 
Our previous mutations at Q67, I68 and Y69 in the context of the homotetramer 
(i.e. 4 mutations per active site pore) show minimal to no changes in NADPH 
cooperativity over a 1000 fold change in binding affinity (1,7).  We previously 
interpreted this result as indicating either changes in affinity occur at all symmetry related 
sites leading to similar effects and/or that interligand cooperativity is quite important in 
ligand binding/catalysis.  This is the first case where significant changes in NADPH 
cooperativities have been observed in R67 DHFR.  Essentially no cooperativity between 
2 NADPH molecules is observed for the Q67H:1+4 double mutant while a 17 fold 
difference exists between the Kd values for the Q67H:1+2+3 mutant.  Further the 
DHF•DHF interaction varies dramatically with Quad 3 displaying positive cooperativity 
and the Q67H:1+4 mutant possessing either independent sites or negative cooperativity.  
The range of Kd2/Kd1 for DHF binding varies from 0.043 to 340, a 7,900 fold effect.  
Formation of the NADP+•DHF ternary complex also shows effects over a 10 fold range. 
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That the cooperativity between NADP+ and DHF is least affected suggests a preference 
for the hetero-ligand complex, a catalytic advantage that R67 DHFR utilizes.   
Figure 5 compares the cooperativities between the various 2 ligand complexes, where 
cooperativity measures the Kd for binding of the second ligand divided by the Kd for 
binding the first ligand.  Quad 3 shows negative cooperativity between the 2 NADPH 
molecules, positive cooperativity between the two DHF molecules and positive 
cooperativity between NADP+ and DHF, i.e. ternary complex formation.  To increase 
catalytic efficiency, these traits should either be enhanced or alternately, the strong 
positive cooperativity between the two DHF molecules could theoretically be replaced by 
a strong negative cooperativity.  Negative cooperativity patterns are observed for the 
Q67H:1+3 and Q67H:1+4 double mutants.  How does this translate into steady state 
kinetic behavior?  Also the cooperativity ratios for the triple mutant show the most 
convergence.  Does this correlate with an inability to discriminate between the various 
complexes? 
Patterns of steady state kinetic behavior 
As discussed above, 2 issues arise in R67 DHFR catalysis.  The first is 
stabilization of the productive ternary complex leading to the transition state.  The second 
issue arising from the 222 symmetry of the active site pore is competing formation of 
inhibitory complexes.  To express this in an energy landscape perspective, R67 DHFR 
binds 3 complexes, DHF•DHF, NADPH•NADPH or NADPH•DHF.  To enhance  
catalysis, R67 DHFR can either stabilize the NADPH•DHF complex and/or destabilize 
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Figure 5.  A bar graph comparing cooperativity ratios for the various protein 
constructs.  The cooperativity between the first and second bound NADPH molecules 
(hatched bar) is described by Kd2 / Kd1 (see Table 4).  The cooperativity between the 
DHF molecules (light gray bar) is given by Kd2 / Kd1 (see Table 4).  The cooperativity 
between NADP+ and DHF (dark gray bar) is given by Kd DHF ternary / Kd NADP+ binary (see 
Table 5).  Data for the Q67H homotetramer were from reference 1.  
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the NADPH•NADPH and DHF•DHF complexes.  The latter approach is termed negative 
design (33-35). 
This second issue arises when considering the steady state kinetic behavior of the 
Q67H mutation series.  Increasing levels of substrate/cofactor inhibition are noted as the 
number of mutations increases, with Quad 3 showing no evidence of inhibition in the 
assay concentrations used (6-121µM NADPH, 4-112 µM DHF), the double mutants 
exhibiting zero to moderate levels of inhibition and the triple and quadruple mutants 
displaying severe inhibition.  Quad 3 appears to have evolved a reasonable binding 
surface that achieves a low free energy state for the NADPH•DHF complex coupled with 
a large free energy difference between productive and non-productive complexes.  While 
addition of Q67H mutations slightly alters binding to the NADPH•DHF complex, a large 
energy difference between the NADPH•DHF complex and the NADPH•NADPH and 
DHF•DHF states is no longer maintained, resulting in increasing levels of inhibition.  
The competition between the three ligation states can clearly be seen in the 3D 
plots describing bisubstrate kinetics.  We begin this discussion considering the simple 3D 
plot for Q67H:1 which shows no inhibition at the concentrations shown (figure 4a).  
Hyperbolic (2D) plots can be seen on all 4 vertical edges of the cube and a plateau can be 
seen at the upper back corner of the cube as Q67H:1 approaches its kcat value (0.23 sec-1) 
at a 1:1 ratio of DHF to NADPH.  In contrast, the Q67H homotetramer (Figure 4b) shows 
that at low levels of DHF, addition of NADPH is inhibitory due to formation of the 
NADPH•NADPH complex (2D plot on right face of cube).  At high concentrations of 
NADPH, addition of DHF displays hyperbolic kinetics (back face of cube), but since the 
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enzyme is strongly inhibited due to formation of the NADPH•NADPH complex, the only 
possibility is for the activity to rise.  This curve does not reach kcat (0.025 sec-1) as there is 
always some level of inhibition present.  At low levels of NADPH, addition of DHF is 
inhibitory due to formation of the DHF•DHF complex (front face of cube).  At high 
concentrations of DHF, addition of NADPH shows initial hyperbolic kinetics followed by 
inhibition (left face of cube).  Again since the enzyme is strongly inhibited under these 
high DHF conditions, the activity can only increase.  The rate increases until the NADPH 
concentration becomes high enough to be inhibitory and the NADPH•NADPH complex 
forms (back corner of cube).  The kcat is never reached anywhere on the surface of this 3D 
plot.  A “ridgeline” that describes maximal activity can be clearly seen.  The “ridgeline” 
appears to correspond to a 1:1 ratio of DHF to NADPH, modified by the relative 
inhibitory capacities of the DHF•DHF to the NADPH•NADPH complexes.   
Another way to consider the kinetic results is that the cooperativity patterns for 
the various double mutants vary substantially, yet kcat is barely affected. This behavior 
indicates the cooperativity associated with reaching the productive ternary complex state 
has not changed dramatically (see Table 5).  What has changed is the ability of the 
NADPH•NADPH and/or DHF•DHF complexes to compete favorably for formation.  
When these dead-end complexes readily form, the ability of the mutant enzyme to reach 
kcat decreases.  This is clearly shown in Figure 4b for the Q67H homotetramer. 
Role of Q67H in interligand interactions? 
Gene duplication followed by divergence is commonly proposed as a mechanism 
of enzyme evolution.  In this study, we quadruplicated the gene for R67 DHFR and 
 75
introduced various combinations of Q67H mutations.  While addition of the Q67H 
mutation in the homotetramer tightens binding to both ligands by a factor of 100, this 
effect does not appear in an additive fashion as increasing numbers of Q67H mutations 
are added asymmetrically to the quadruplicated gene product.  This study of gradually 
breaking the symmetry of the binding surface suggests one consequence of the symmetry 
is overdetermination of the binding interactions, particularly for the heteroligand 
complex.  While addition of a single Q67H mutation might be expected to provide one  
mutation has minimal effects on catalysis.  For example while similar Kd values for tight 
binding interaction that would enhance binding, we find introduction of a single binding 
two DHF molecules leads to the prediction of DHF inhibition in the Q67H:1 variant, 
none is observed.  This suggests the remaining wt sites maintain their function and are 
strongly preferred during catalysis.  If a pair of Q67 residues need to interact to provide 
one tight binding surface, then the Q67H:1+4 double mutant would be expected to 
enhance binding as these mutations form a pairwise interaction.  This double mutant 
shows larger effects on ligand binding, but minimal effects on kcat, again suggesting an 
overdetermination of the binding sites with a preference for wt sites.  As 3-4 mutations 
are added, increasing effects on catalysis are noted, with the ability of the enzyme to 
discriminate between the productive ternary complex and nonproductive homoligand 
complexes becoming compromised.  While the 222 symmetry in R67 DHFR imposes 
numerous deleterious effects on binding and catalysis, overdetermination of the binding 
site suggests an evolutionary advantage for symmetry as asymmetric mutations are 
introduced. 
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An alternate, but linked, point of view suggests that while protein interactions are 
important, the symmetry in R67 DHFR has selected for a strong influence arising from 
hetero-ligand interactions. While the NADP+•DHF complex is not the catalytic species, it 
provides a reasonable mimic.  The ternary complex Kd values (Table 5) as well as the kcat 
values (Table 1) suggest that the hetero-ligand interactions are maintained (for the most 
part) in all the asymmetric mutants and perhaps drive binding.  Additional support for 
this point of view comes from an ab initio quantum mechanical calculation that predicts 
the endo transition state  (where the nicotinamide ring overlaps the more bulky side of the 
pteridine ring) is 2-8 kcal/mol more stable than the exo transition state (with minimal 
overlap of the pteridine and nicotinamide rings; 36,37).  Interligand NOE NMR data also 
favor R67 DHFR using an endo transition state (5) as do our docking studies focused on 
generating a ternary complex model (6).  Some degree of ring stacking may allow R67 
DHFR to partition binding towards the ternary complex.    
While Q67 appears to play a minimal role in formation of the NADPH•DHF 
complex, it appears more active in discriminating against formation of the 
NADPH•NADPH and DHF•DHF complexes.  To describe how the Q67H mutations 
affect the 2DHF and 2NADPH complexes will require better models of these complexes.  
From the crystal structure of R67 DHFR•folate•folate, the N1 and N3 containing rings of 
the pteridine moieties overlap (3).  More recent studies monitoring interligand NOEs 
(ILOEs) in R67 DHFR (5) describe a folate•2-deamino-2-methyl-5,8-dideazafolate 
complex with a similar overlap of the N1, N3 containing rings of the pteridines.  In 
contrast, no structural information is available about the NADPH•NADPH complex.  
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How does R67 DHFR differentiate between these various complexes?  Perhaps a clue 
comes from our ITC studies that measure the enthalpies associated with ligand binding.   
Figure 6 shows a plot of ∆H vs. T∆S for the various complexes.  Binding can be 
altered in mutant enzymes by different degrees of hydrogen bonding and van der Waals  
contacts which in turn can alter the degrees of freedom of the ligand and amino acid side 
chain (38,39).  The former would affect ∆H, the latter, T∆S.  Solvent re-organization may 
be involved in the effects of different ligands and mutant enzymes on ∆H and T∆S 
(40,41).  Finally any proton exchange between enzyme and buffer to which ligand 
binding may be coupled could also be perturbed by use of a different mutant and result in 
a concomitant change in the thermodynamics of ligand binding.  With these caveats in 
mind, it is worth noting that all the asymmetric proteins in this series show binding of 
DHF to the R67 DHFR•NADP+ complex is enthalpy driven.  When trends within an 
enzyme variant are considered, most of the binary binding interactions for Quad 3 are 
enthalpy driven as are those for the Q67H:1+4 mutant.  In contrast, binding in the other 
mutants is driven by both thermodynamic components (enthalpy and entropy).    
Calderone & Williams (42) suggest structural tightness displays a positive 
correlation with the exothermicity of the binding interaction.  Maintaining enthalpy- 
driven formation of the ternary complex in these Q67H asymmetric mutants suggests a 
strong role for enthalpy in catalysis.  Our studies support recent reports of catalytic 
function that suggest a strong role for enthalpy (43-51). 
To conclude, formation of the R67 DHFR•DHF•NADP+ ternary complex is  
enthalpy driven, and introduction of Q67H mutations does not drastically affect its 
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Figure 6.  A plot of entropy (T∆S) versus enthalpy (∆H) for various mutants and 
ligands. Binding data from Quad 3, Q67H:1, Q67H:1+2, Q67H:1+3, Q67H:1+4, 
Q67H:1+2+3 and the Q67H homotetramer proteins (1) are included.  Values for binding 
the first and second NADPH molecules are given by ? and gray filled circles.  Values 
for binding the first and second DHF molecules are given by ? and gray filled squares.  
Values for binding NADP+ are shown by ? and values for DHF binding to R67 
DHFR•NADP+ are given by g points.  The slope of the line is 0.85 and the correlation 
coefficient is 0.87.  A plot of ∆H versus ∆G shows no correlation (not shown).   
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formation.  This result suggests a strong role for interligand (NADP+ to DHF) 
interactions in complex formation.  (Presumably interligand interactions would be 
important in the NADPH•DHF complex as well).  Further, addition of increasing 
numbers of Q67H mutations results in the inability of the enzyme to discriminate 
between the productive and nonproductive complexes.  These results support a role for 
Q67 in minimizing formation of the NADPH•NADPH and DHF•DHF complexes.   
The Q67H:1+4 double mutant remains an interesting mutant as it displays  
minimal NADPH and DHF inhibition and it tightly binds the productive ternary complex 
(∆H in table 5 as well as maintains its kcat/Km (NADPH) value).  This mutant may serve as a 
stepping stone for addition of other asymmetric mutations, leading to design of an 
alternate active site constellation with half the pore preferentially binding DHF and the 
other half binding NADPH.  Further, we anticipate addition of asymmetric mutations at 
positions further away from the 222 symmetry operator will allow ready analysis of their 
effects as these substitutions will not be involved in the pairwise interactions that occur at 
the unusual position at the center of the pore. 
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Figure 7. Steady state kinetic data for Q67H:1+3 (top panel) and Q67H:1+4 
R67 DHFRs (bottom panel).  Nonlinear fitting to equation 1 was performed 
using SAS and Table 1 gives the best fit values.  Data points above and 
below the calculated 3D plot are filled and hollow stars respectively.  Kd 
values derived from ITC data were used as constraints in fitting with 2-3 fold 
variations accepted if the ITC data could be reasonably refit with these 
values.   
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Figure 8. A series of fluorescence titration curves monitoring the equilibrium 
between “open” and “closed” forms of Quad 3 and its mutants.  This equilibrium 
corresponds to titration of H62 residues.  In wt R67 DHFR, titration of H62 is 
linked to a tetramer to 2 dimers equilibrium (11-12).  Fluorescence data were 
converted to a fraction to aid comparison.  The ? points and solid line 
correspond to the Quad 3 protein; the ∆ points and the dashed line correspond to 
the Q67H:1 mutant; the ? points and dotted line correspond to the Q67H:1+2 
double mutant.  The other 4 proteins are not shown for clarity.  Best fit pKa 
values associated with the titrations are given in the Table 6. 
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Table 6. A comparison of pKa values describing titration of Quad 3 variants from a 
“closed” to an “open” form as monitored by fluorescence. 
 
DHFR Variant pKa 
Quad 1a 5.5 
Quad 3 5.74 ± 0.01 
Q67H:1 5.92 ± 0.02 
Q67H:1+2 6.22 ± 0.02 
Q67H:1+3 6.02 ± 0.03 
Q67H:1+4 6.00 ± 0.02 
Q67H:1+2+3 6.11 ± 0.03 
Q67H:1+2+3+4 6.06 ± 0.07 
                                    a  Value from reference 12. 
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Abstract 
R67 dihydrofolate reductase reduces dihydrofolate to tetrahydrofolate where the 
cofactor, NADPH, is required for the hydride transfer reaction.  The homotetrameric 
enzyme provides a unique environment for catalysis as both ligands bind within a single 
active site pore.  Mutation of one active site residue results in concurrent mutation of 
three additional symmetry related residues, and large effects on binding of both ligands as 
well as catalysis.  For example, mutation of symmetry related tyrosine 69 to 
phenylalanine (Y69F), results in large increases in Km values for both ligands and a two 
fold rise in the kcat for the reaction [Strader, M. B. et al. (2001) Biochemistry 40, 11344-
11352].  To understand the interactions between specific Y69 residues and each ligand, 
asymmetric Y69F mutants were generated which contain one, two, three, or four Y69F 
mutations.  A general trend observed from isothermal titration calorimetry and steady-
state kinetic studies of these asymmetric mutants is that increasing the number of Y69F 
mutations results in an increase in the Kd and Km values.  In addition, a comparison of 
steady state kinetic values suggests that two Y69 residues on one side of the active site 
pore are necessary for NADPH to exhibit a wild-type Km value.  A tyrosine 69 to leucine 
 91
(Y69L) R67 DHFR homotetrameric mutant was also generated to approach the type(s) of 
interaction(s) occurring between Y69 residues and the ligands.  These studies suggest that 
the hydroxyl group of Y69 is important for interactions with NADPH while both the 
hydroxyl group and benzene ring of the Y69 residues are necessary for proper 
interactions with dihydrofolate.   
Introduction 
Dihydrofolate reductase (DHFR) catalyzes the reduction of dihydrofolate (DHF) 
to tetrahydrofolate (THF) via hydride transfer from its cofactor NADPH.  DHFR is 
necessary for cell survival as THF is involved in pathways leading to the synthesis of 
purine nucleosides and other metabolites (1).  The chromosomal (E. coli) form of DHFR 
is inhibited by trimethoprim.  However, R67 DHFR, a plasmid encoded DHFR, has been 
found to provides resistance to the antibiotic ((2) and references therein).  The plasmid 
encoded DHFR is unique in that it shows no structural (3, 4) or genetic (2) homology to 
chromosomal DHFR.   
R67 DHFR1, shown in Figure 1, is composed of four identical monomers that 
associate to form the apoenzyme.  Each monomer is made up of 78 amino acids that form 
five β-barrel strands oriented antiparallel to one another.  The tetramer is classified as a 
D2 symmetric enzyme that possesses 222 symmetry (3).  Crystallographic data have 
indicated that a pore, 25 Å long, extends through the center of the enzyme.  The size of  
                                                 
1 The monomers of R67 DHFR are labeled ABDC going in a clockwise orientation in the 
crystal structure (1VIE and 1VIF in the Protein Data Bank).  The residues in monomer A 
are labeled 1-78, while those in monomers B, C, and D are designated 101-178, 201-278, 
and 301-378, respectively.  All four symmetry related residues are implied when one 
residue of the homotetramer is described.  The corresponding domains in Quad 3 are 
relabeled 1234.   
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Figure 1.  A ribbon structure of R67 DHFR (protein data bank file 1VIE).  Panel A 
shows a front view of the R67 DHFR structure, where the active site pore 
corresponds to the “doughnut hole” in the center.  Monomers are relabeled clockwise 
as 1, 2, 3, and 4 (green, yellow, magenta and cyan) respectively.  Each monomer 
corresponds to a domain in the Quad 3 construct.  The protein crystallized had its 16 
N-terminal residues removed by chymotrypsin treatment (2, 21).  Y69 residues are 
indicated by CPK surfaces.  Panels B-D illustrate the topologies associated with the 
various double mutants.  These views are related to that in panel A by a 90o rotation 
along the y-axis.  Wild-type Y69 residues are shown as CPK surfaces while Y69F 
mutants are shown as ball-and-stick structures.  Panels B and D represent the Y69F: 
1+2 and Y69F: 1+4 mutants where each half of the pore contains one Y69 and one 
Y69F residue.  Panel C shows the Y69F: 1+3 mutant where one half of the pore 
contains two 69 residues and one half of the pore contains two Y69F residues.  Panel 
E shows a reverse image of the active site pore generated by DOCK (13, 24-25).  
Each white sphere corresponds to a potential atom position used by the docking 
program.  This sphere cluster was generated from panel A by a 90o rotation around 
the x and y axes.  The reverse image compares to panels B-D by a 90o rotation along 
the x axis.  The position of a docked NADPH molecule that meets the NMR 
constraints is shown in red and the position of the highest scoring docked folate 
molecule is shown in orange (13).  Stacking between the nicotinamide ring of 
cofactor and pteridine ring of folate is predicted near the center of the pore.  The 
positions of the 4 symmetry related Y69 residues in the surrounding protein are 
colored and numbered as described above.  The rest of the protein is not shown for 
simplicity.   
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the pore decreases towards the center of the enzyme due to interactions between 
symmetrically related glutamine residues (Q67).  Hydrogen bonding interactions between 
these residues to create “a floor and ceiling” in the pore and a proposed area for binding 
of substrate (DHF)2 and cofactor (NADPH) (3).   
In addition to the structure for the apoenzyme, a crystal structure for a binary 
enzyme-folate complex has also been solved (3).  In this crystal structure, the largest 
accumulation of electron density for folate is observed near the pore’s center.  This 
electron density is most consistent with two folate molecules binding in the pore in 
slightly different orientations.  Specifically, FolI is proposed to bind in the pore in an 
orientation where its si face is available for hydride transfer from NADPH.  In contrast, 
FolII is bound such that its si face cannot be accessed (3).  NMR studies previously 
conducted on a variant of R388 DHFR, a homolog of R67 DHFR, indicate that the pro-R 
hydrogen is transferred from NADPH to the same face of DHF during the reaction (5).  
Thus, only FolI is in the proper orientation to accept a hydride during catalysis (3). 
  In contrast to folate, attempts at generating co-crystals for NADPH or NADP+ 
have to date proven unsuccessful.  However, NMR studies indicate that the nicotinamide 
of the cofactor also interacts with the pteridine ring of folate in the pore’s center as 
                                                 
2 Abbreviations:  DHFR, dihydrofolate reductase; TMP, trimethoprim; DHF, 
dihydrofolate; THF, tetrahydrofolate; NMNH, reduced nicotinamide mononucleotide; 
NADP(+/H), oxidized/reduced nicotinamide adenine dinucleotide phosphate; PABA-
glutamic acid tail, para-aminobenzoyl glutamic acid region of dihydrofolate/folate; ITC, 
isothermal titration calorimetry; CD, circular dichroism; and Quad 3, the protein product 
of a tandem array of four in-frame R67 DHFR genes.  Mutations are indicated by listing 
the wild-type residue and its location in the amino acid sequence followed by the residue 
to which it is mutated.  For example, mutation of tyrosine at position 69 to phenylalanine 
will be represented as Y69F.   
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interligand NOEs were observed between NADP+ and a folate analog (6).  Chemical 
shifts upon ligand binding also suggest that numerous residues comprising the active site 
pore are involved in interactions with NADP+ (7). 
 This present series of experiments examines the means by which NADPH and 
DHF interact with R67 DHFR.  Since limited structural evidence is available, we have 
approached this problem by mutagenesis of specific residues within the active site that 
are proposed to facilitate ligand binding and/or catalysis.  Site-directed mutagenesis of 
most of the residues proposed to comprise the active site surface has been performed (8-
10).  Because R67 DHFR is composed of 4 symmetry-related monomers, mutation of one 
residue results in 4 symmetry related mutations which often have large effects on kinetic 
and thermodynamic parameters (9).  Therefore, our goal has been to generate a system by 
which we can control the number and location of the mutation(s) by building asymmetric 
mutants where only defined subunits of the tetramer are mutated (11, 10, 12).  To 
approach this goal, Bradrick et al. (12) constructed “quadruple R67 DHFR”.  The gene 
coding for quadruple R67 DHFR contains four in-frame copies of the DNA encoding 
wild-type R67 DHFR.  Transcription and translation yield a monomeric protein 
mimicking the wild-type protein.  Each domain in quadruple R67 DHFR equates to a 
monomer in the homotetramer.  Unique restriction enzyme sites, flanking the tandem 
gene copies, were later engineered into the construct, allowing for removal of the DNA 
coding for a specific domain followed by its replacement with DNA containing the 
specified mutation(s).  Each of the asymmetric mutants described below were generated 
in the Quad 3 construct, which has been previously described (11). 
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These present experiments explore the role of symmetry related tyrosine 69 
residues in ligand binding and catalysis.  Docking studies suggest that these symmetry 
related residues may play a role in binding both the substrate and cofactor (13).  Two 
symmetry-related tyrosine 69 residues are proposed to form contacts with the 
pyrophosphate bridge of NADPH as well as with the adenine ribose.  Docking studies 
also predict a possible interaction between the tyrosine hydroxyl and the glutamic acid 
tail of folate (13).  Kinetic studies of the homotetrameric Y69F mutant also support the 
hypothesis that Y69 interacts with both DHF and NADPH, as the Km values for DHF and 
NADPH are 11 and 17 fold weaker respectively than those for wild-type R67 DHFR (9).  
In addition, the kcat for the reaction is two fold greater than the kcat for wild-type R67 
DHFR.  These data indicate that although binding of both substrate and cofactor is 
weaker, the rate at which the reaction proceeds is faster (9).    
Our approach to understanding the role of symmetry related tyrosine 69 residues 
in ligand binding and catalysis is two-fold.  First, we generated a series of asymmetric 
Y69F mutants including a single mutant (containing one Y69F mutation), three double 
mutants (each containing two Y69F mutations), a triple mutant (containing three Y69F 
mutations), and a quadruple mutant (containing four Y69F mutations) to better 
understand the specificity of the interactions between Y69 and both DHF and NADPH.  
This approach allows us to determine if there is a preference for NADPH and/or DHF to 
interact with wild-type tyrosine 69 residues.  Our second approach involved site-directed 
mutagenesis of tyrosine 69 residues within the homotetrameric enzyme in order to better 
understand the type(s) of interaction(s) occurring between symmetry related tyrosine 69 
and the ligands and how these interactions are involved in catalysis.    
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Materials and Methods 
Construction of asymmetric Y69 mutants: 
Asymmetric Y69F mutants were generated by PCR based site-directed mutagenesis as 
previously described (11) using the following primer: 
Y69F forward:  5′ - GGCTCAGTACAGATCTTCCCTGTTGCGGCG - 3′ 
Correct mutations were confirmed using ABI Prism Automated Sequencing at the 
University of Tennessee DNA sequencing laboratory.  DNA containing the appropriate 
mutations was transformed into E. coli STBLII cells (14).  Cells were grown overnight at 
30°C on Luria broth agar plates containing 200 µg/ml ampicillin and 20 µg/ml 
trimethoprim to assay for trimethoprim resistance.  All six Y69F asymmetric mutants 
provided resistance to trimethoprim as evidenced by their ability to allow host E. coli to 
grow on LB plates containing 20µg/ml of trimethoprim.   
 Y69T, Y69K, Y69Q, and Y69L homotetrameric mutants were generated by PCR 
based site-directed mutagenesis using the following primers: 
Y69T forward:  5′ - GGCTCAGTACAGATCACTCCTGTTGCGGCG - 3′ 
Y69K forward: 5′ - GGCTCAGTACAGATCAAACCTGTTGCGGCG - 3′  
Y69Q forward: 5′ - GGCTCAGTACAGATCCAGCCTGTTGCGGCG - 3′ 
Y69L forward:  5′ - GGCTCAGTACAGATCCTTCCTGTTGCGGCG - 3′ 
None of the cell lines transformed with these Y69 mutants were able to grow in the 
presence of TMP.  Therefore, only the Y69L mutant was pursued.  
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Protein expression and purification 
For Y69F asymmetric mutant protein expression, STBLII cells were grown at 
30°C in TB media (15) containing 200µg/ml ampicillin and 20µg/ml trimethoprim for 
approximately 60 hours.  Cells were lysed by sonication, and protein was precipitated 
with 55% ammonium sulfate.  Proteins were purified (as determined by SDS-PAGE) 
using a variety of chromatography columns as described previously (1).  PEG3350 (0.1g/L) 
was added to the buffer to decrease aggregation and is present in most experimental 
conditions (16).  Extinction coefficients for the asymmetric mutants were determined by 
biuret analysis (17).     
Steady-state kinetics 
Steady-state kinetics were performed for each of the mutants to determine the 
corresponding Km and kcat values.  Experiments were performed at 30°C on a Perkin-
Elmer Lambda 3B UV/Vis spectrophotometer using UVSL3 software.  Experiments were 
conducted in MTH buffer (50 mM Mes, 100 mM Tris and 50 mM acetic acid with 10 
mM β-mercaptoethanol) at pH 7.0.  Data were collected for five sub-saturating 
concentrations of NADPH and five sub-saturating concentrations of DHF.  The data were 
analyzed using SAS as described previously (11) using global, non-linear least squares fit 
to a bi-substrate mechanism (18).   This software is available on the internet at: 
http://www.agriculture.utk.edu/ansci/faculty/saxton_software.html. 
Isothermal titration calorimetry (ITC) 
Isotherms were generated for substrate or cofactor binding to each asymmetric 
mutant on a Microcal VP isothermal titration calorimeter at 28°C.  Mes-Tris-acetic acid 
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buffer at pH 8 was used for NADPH binding studies while 10 mM Tris + 1 mM EDTA 
buffer pH 8 was used for DHF binding studies.  As DHF is a weak acid, the pH of the 
DHF solution was titrated with NaOH to ~ pH 8 prior to ligand binding studies.  The data 
for NADPH binding to each of the Y69F asymmetric mutants were analyzed by Origin 
software (Version 5.0) using both the single sites model and the sequential sites model 
where the stoichiometry was set to two.   
Circular dichroism 
To determine whether the Y69F asymmetric mutations in Quad 3 and/or the Y69L 
mutations in homotetrameric R67 DHFR had affected the overall secondary structure of 
the protein, circular dichroism (CD) experiments were performed on an AVIV 202 
circular dichroism spectrophotometer at 22°C in phosphate buffer at pH 8.  Data were 
collected for 10µM protein samples between 190 and 300nm at 2 or 3nm steps (9).  
pH titrations 
Homotetrameric R67 DHFR dissociates into dimers upon titration with acid due 
to protonation of symmetry related histidine 62 residues (19, 20).  This dissociation 
process can be monitored by a change in fluorescence of symmetry related tryptophan 
residues which become solvent exposed upon dissociation of the tetramer (19-21).  In 
order to determine if Y69L mutations in the homotetramer had affected this equilibrium, 
pH versus fluorescence intensity profiles were generated.  Data were fit as described 
previously by non-linear regression using SAS (9, 19, 20).  Although the Y69F 
asymmetric mutants are unable to undergo a dimer to tetramer equilibrium as the 
domains are covalently linked, it is possible for the domains to “open up” or “splay apart” 
upon titration of symmetry related histidine 62 residues (11, 12).  This process can also 
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be monitored as a change in tryptophan fluorescence as pH is decreased.  To determine 
whether Y69F asymmetric mutations had affected this process, pH versus fluorescence 
intensity profiles were generated.  Data were fit to a simple ionization equation using 
Sigmaplot (22). 
Results 
Nomenclature 
The following nomenclature will be used to describe each of the asymmetric 
mutants.  The residue, residue number, and mutation will be listed first followed by a 
colon.  The asymmetric location of the particular mutations will be indicated numerically 
where 1 refers to domain 1, 2 refers to domain 2, etc.  This is illustrated using the crystal 
structure for homotetrameric R67 DHFR in Figure 1 where each monomer would 
correspond to a domain in Quad 3 (3, 23)  The four domains are labeled in a clockwise 
fashion where domain 1 is located at the bottom, left position.  For example, the Y69F: 
1+3 mutant contains two mutations:  tyrosine 69 in domain 1 has been mutated to a 
phenylalanine residue, as has tyrosine 69 located in domain 3.  Figure 1 also compares 
the different topologies of the three double mutants.  For the Y69F: 1+3 mutant, one side 
of the pore contains wild-type Y69 residues while the opposite side of the pore contains 
mutant Y69F residues (panel C).  In contrast, both the Y69F: 1+2 and Y69F: 1+4 mutants 
contain one Y69 and one Y69F residue on each side of the pore (panels B and D), 
although with different distances between the mutations.  Because Y69 residues are 
located further away from the center of symmetry, these residues likely interact with the 
ADP-ribose and/or the PABA-glutamic acid tails of NADPH and DHF, respectively (3, 
13).  Figure 1E displays the relative positions of the Y69 residues with respect to a  
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docked ternary complex model that incorporates NMR and X-ray crystallography 
information (3, 6, 7, 13). 
In addition to Y69F asymmetric mutants, the effects of Y69L mutations in the  
homotetrameric enzyme were also assessed.  This construct will be referred to as Y69L 
R67 DHFR and contains four symmetry-related Y69L mutations.  For clarity, the data for 
the Y69F asymmetric mutants will be discussed first, followed by that for Y69L R67 
DHFR.      
Steady-state kinetics 
 In order to gain a better understanding of the effects of Y69 mutations on 
catalysis, steady-state kinetic data were collected for each of the asymmetric Y69F 
mutants.  The kinetic results are presented in Table 1.  In general, the Km values for 
NADPH and DHF as well as the kcat display a trend contingent upon the location and 
number of Y69F mutations.  A wild-type Km (NADPH) value is observed for both the Y69F: 
1 and Y69F: 1+3 mutants, while the Km (NADPH) for the Y69F: 1+2 and Y69F: 1+4 mutants 
is ~3-4 fold weaker.  The Km (NADPH) for the triple mutant (Y69F: 1+2+3) continues to rise 
as does the Km (NADPH) for the quadruple mutant (Y69F: 1+2+3+4).  The kinetic 
parameters for the Y69F: 1+2+3+4 mutant are similar to those for Y69F R67 DHFR.  
Thus, for NADPH binding interactions in the productive, ternary complex, as the number 
of mutations is increased, Km (NADPH) is increased.  The two exceptions to this trend are 
the Y69F: 1 and Y69F: 1+3 mutants.  However, these two mutants are similar in that they 
are the only mutants in which an entire “side” of the pore is wild-type.  This suggests that 
for NADPH to bind in a manner similar to that of the wild-type enzyme, it is necessary 
for one side or half of the pore to remain wild-type.   
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Table 1.  A comparison of kinetic parameters for wild-type R67 DHFR, Quad 3 DHFR, 
Y69F asymmetric mutants, Y69L R67 DHFR, and Y69F R67 DHFR at pH 7.0.   
 
Enzyme Variant 
 
kcat 
(sec-1) 
Km (NADPH) 
(µM) 
Km (DHF) 
(µM) 
WT R67 DHFRa 
 
1.3 ± 0.073  3.0 ± 0.060 5.8 ± 0.015 
Quad 3 DHFRb 0.81 ± 0.02 4.4 ± 0.4 6.7 ± 0.4 
Y69F: 1 DHFR 0.98 ± 0.06 6.4 ± 0.6 21 ± 2 
Y69F: 1+2 DHFR 
 
0.96 ± 0.01 14 ± 0.8 20 ± 0.9 
Y69F: 1+3 DHFR 
 
0.56 ± 0.01 3.1 ± 0.4 20 ± 2 
Y69F: 1+4 DHFR 
 
1.9 ± 0.08 14 ± 0.7 28 ± 2 
Y69F: 1+2+3 DHFR 
 
1.4 ± 0.04 21 ± 0.9 35 ± 2 
Y69F: 1+2+3+4 DHFR 
 
1.4 ± 0.04 40 ± 3 54 ± 3 
Y69F R67 DHFRc 2.9 ± 0.1 69 ± 3 68 ± 4 
Y69L R67 DHFR 0.16 ± 0.01 68 ± 3 180 ±11 
    a Taken from (23). 
    b Taken from (11). 
    c Refit from (9) using the non-linear, global SAS fit described in (11).  
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 Similar to NADPH interactions in the ternary complex, Km (DHF) values also tend 
to increase as the number of mutations is increased.  Specifically, the Km (DHF) for the 
single and all the double mutants is ~2-3 fold weaker than the Km (DHF) for Quad 3.  In 
addition, the Km (DHF) for the Y69F: 1+2+3 mutant continues the trend of increasing as 
additional mutations are added, up to the limit associated with the Y69F: 1+2+3+4 
mutant.       
 Although binding of both NADPH and DHF in the Michaelis complex is, in 
general, weakened as the number of Y69F mutations is increased, the kcat value is 
increased.  The kcat values vary over an approximately 2 fold range.  A trend is noted 
where the kcat increases when two Y69F mutations occur in either the “ceiling” and or the 
“floor” of the active site pore as occurs in the Y69F: 1+4, Y69F: 1+2+3 and Y69F: 
1+2+3+4 mutants, suggesting this topology may be preferred in the transition state.    
Isothermal titration calorimetry 
 Although steady-state kinetics provide important insight into interactions between 
ligands in the Michaelis complex, these Km values do not necessarily correspond to 
dissociation constants (Kds) as other events can contribute to the observed Km values 
(22).  Isothermal titration calorimetry provides a direct measure of the heat exchange 
upon ligand binding as well as a direct measure of the dissociation constant for the ligand 
of interest (26, 27).  In order to determine the effects of the asymmetric Y69F mutations 
on NADPH and DHF binding, isothermal titration calorimetry experiments were 
performed for the binary complexes where either two NADPH molecules or two DHF 
molecules interact with the enzyme.  Data for NADPH binding to the Y69F asymmetric 
mutants are summarized in Table 2.  These data were analyzed using both the single sites  
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Table 2.  Comparison of NADPH binding constants for Y69F asymmetric mutants and 
Y69L R67 DHFR as determined by isothermal titration calorimetry.  Data reported were 
fit using the single sites model.  Each value is an average of at least two different 
experiments (except Y69F R67 DHFR).   
 
 
     
Complex 
  
                  
Kd (µM) ∆H (cal/mol) Stoichiometry 
Quad 3 DHFR 8 ± 0.3 -7600 ± 260 0.83 ± 0.01 
Y69F: 1 DHFR 10 ± 1 -6200 ± 120 0.88 ± 0.003 
Y69F: 1+2 DHFR 25 ± 2 -4900 ± 170 0.69 ± 0.02 
Y69F: 1+3 DHFR 15 ± 1 -5200 ± 390 0.72 ± 0.01 
Y69F: 1+4 DHFR 9 ± 1 -7500 ± 490 0.84 ± 0.02 
Y69F: 1+2+3 DHFR 
 
25± 2 -5000 ± 120 0.75 ± 0.03 
Y69F: 1+2+3+4 DHFR 52 ± 5 -2400 ± 210 0.95 ± 0.11 
Y69F R67 DHFRa 65 ± 6 -2200 ± 170 1.1 ± 0.1 
Y69L R67 DHFR 75 ± 0.4 -2800 ± 40 1.1 ± 0.1 
                  
                       
                  
                 
                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
               a Refit from (9) to a single sites model. 
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model and the sequential sites model where the stoichiometry was set to two.  The Kd and 
∆H values for the first NADPH binding event were similar regardless of the model used 
to describe the data.  However the Kd2 and ∆H2 values generated using the sequential sites 
model varied, most likely since the Kd2 values are high and fall outside of the detection 
window afforded by the calorimeter.  For accurate results, the c value, where c is defined 
as [protein]*Ka, should occur within a range of 1 and 1000 (26, 27).  Therefore, only the 
values for the first NADPH binding event are reported.   
In general, the effects of the Y69F mutation(s) on NADPH binding to the single 
and double mutants are minor, with the Y69F: 1+2 configuration having the most 
dramatic effect.  However, as the number of mutations is increased in the triple and 
quadruple mutants, the Kd values also increase.  The enthalpy change for NADPH 
binding to the Y69F: 1 and Y69F: 1+4 mutants is similar to that for Quad 3, while the ∆H 
becomes less negative as the number of mutations is increased in the Y69F: 1+2+3 and 
Y69F: 1+2+3+4 mutants. 
 Isothermal titration calorimetry experiments were also performed to determine the 
effects of asymmetric Y69F mutations on interactions with DHF.  Previously, isotherms 
generated for DHF binding to wild-type R67 DHFR were fit to an interacting sites model 
as isotherms displayed a hook reflecting positive cooperativity between bound DHF 
molecules (28).  New calorimeters have increased sensitivity to minor changes in solution 
pH during the titration.  Close attention to the pH of both the ligand and protein solution 
indicated that the prominence of the hook is related to changes in pH of the protein 
solution upon injection of ligand into the solution.  Additional studies indicate that the 
presence of the hook is affected by the ionic strength of the buffering solution (data not 
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shown).  This effect is likely due to disruption of electrostatic interactions between 
symmetry related lysine 32 residues and DHF (8).  The sensitivity of DHF binding to R67 
DHFR may also be related to previous NMR studies that found DHF dimerizes in 
solution and this dimerization is affected by ligand concentration (where dissociation 
constants for dimerization are in the mM range), pH as well as ionic strength (29, 30).    
Due to the characteristics of the isotherms generated for DHF binding to the Y69F 
asymmetric mutants, we are unable to consistently fit the data using the Origin software 
provided by MicroCal.  In particular, if there are only a few points in the hook, the Origin 
software does not provide a strong weighting to those points and the fit line does not go 
through them.  Therefore, for comparative purposes, we have overlaid the raw data for 
DHF binding to each of the asymmetric mutants in Figure 2.  Based on the raw data, a 
trend is observed in both the shape of the curve and the initial heat released upon ligand 
binding as well as in the prominence of the hook.  Specifically, there appears to be a 
trend in the DHF concentration required to reach saturation for the asymmetric mutants.  
The signal for Quad 3 increases most dramatically as the DHF concentration is increased; 
this behavior is expected when tight binding occurs.  The steepness of the slope in the 
titrations decreases as the number of mutations is increased.  This suggests that as the 
number of mutations is increased, more ligand is required to reach saturation and thus 
binding interactions are weaker.  In addition, the enthalpy change upon ligand binding 
appears to decrease from ~ -9000 cal/mole for Quad 3 to ~ -6000 cal/mole for the Y69F: 
1+2+3+4 mutant.  Finally, an increase in the prominence of the “hook” in the isotherms is  
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Figure 2.  Isotherms for DHF binding to Y69F asymmetric mutants generated by 
isothermal titration calorimetry.  Data for Quad 3 (○), Y69F: 1 (□), Y69F: 1+2 (∆), 
Y69F: 1+3 (∇), Y69F: 1+4 (◊), Y69F: 1+2+3 (hexagon), and Y69F: 1+2+3+4 (circle 
with dot) mutants are overlaid for comparative purposes.   
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observed as the number of mutations increases, with Quad 3 displaying a minimal hook 
and the Y69F: 1+2+3 and Y69F 1+2+3+4 mutants displaying the most dramatic hooks.  
Physical studies 
One possible effect of engineered mutations is a change in protein conformation.  
Therefore, circular dichroism spectroscopy was used to determine whether Y69F 
asymmetric mutations cause major secondary structural changes in the Quad 3 construct.  
As shown in Figure 3, slight to moderate variations in the CD signals are observed for the 
Y69F asymmetric mutants and are in the range of those previously observed for other 
mutants (9, 11).  It seems most likely these variations are due to minor changes in local 
protein structure and/or to effects of aromatic residues on the CD signal (9, 11, 31).  
Additionally, pH titrations were performed to determine whether the Y69F 
asymmetric mutations affected the structure by altering the transition between the “open” 
and “closed” conformations of Quad 3 mutants.  This equilibrium describes protonation 
of symmetry-related histidine 62 residues upon titration with acid (19, 20).  As the 
proteins are titrated with acid, symmetry-related tryptophan residues become solvent 
exposed allowing the pKa for histidine-62 residues to be determined from the titration 
(11, 19-21).  Figure 4 shows an overlay of several representative titrations for the Y69F 
aymmetric mutants.  The pKa values for each of the Y69F asymmetric mutants are shown 
in Table 3 and are within 0.09 pH units of each other, consistent with minimal structural 
perturbations. 
Homotetrameric Y69L R67 DHFR 
In order to gain a better understanding of the type(s) of interaction(s) formed 
between Y69 and the ligands, DHF and NADPH, site-directed mutagenesis of  
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Figure 3.  Comparison of CD spectra for Y69 mutants.  Wild-type R67 DHFR (solid 
circle with line through circle), Quad 3 (solid line), Y69F: 1 DHFR (long dash), Y69F: 
1+2 DFHR (dotted), Y69F: 1+3 DHFR (medium dash), Y69F: 1+4 (short dash), Y69F: 
1+2+3 DHFR (dash-single dot), Y69F: 1+2+3+4 DHFR (dash-two dots), and Y69L 
R67 DHFR (solid triangle with line through triangle) spectra are overlaid for 
comparative purposes.   
  
 
Figure 4.  pH titrations for select Y69F asymmetric mutants.  Data are plotted as pH 
versus Fapparent.  Actual data are indicated with symbols while lines through the data 
represent the best fit line through the data when H=3 (three his62 residues are 
protonated causing the protein to splay open).  Quad 3 data (∆) and best fit line (short 
dash), the Y69F:1 data (•) and best fit line (solid line), Y69F: 1+2 data (Ο) and best fit 
line (dotted), Y69F: 1+4 data (□) and best fit line (dash-dot), and Y69F: 1+2+3 data 
(▼) and best fit line (medium dash) are overlaid as representative examples of titrations 
for the Y69F asymmetric mutants. 
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Table 3.  Comparison of pKa values for Y69F asymmetric mutants.  Values represent the 
pKa of symmetry-related his62 residues which become protonated upon titration with 
acid. 
 
Complex pKa 
Quad3 DHFRa 5.74 ± 0.01 
Y69F: 1 DHFR 5.73 ± 0.01 
Y69F: 1+2 DHFR 5.73 ± 0.01 
Y69F: 1+3 DHFR 5.75 ± 0.01 
Y69F: 1+4 DHFR 5.78 ± 0.01 
Y69F: 1+2+3 DHFR 5.74 ± 0.01 
Y69F: 1+2+3+4 DHFR 5.81 ± 0.01 
a Taken from (11)
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homotetrameric Y69 to alternative residues including leucine, lysine, threonine, and 
glutamine was performed.  These mutations all resulted in the same phenotype (TMP 
sensitive host E. coli cells), therefore only one mutant, Y69L R67 DHFR, was further 
characterized. 
Similar to the effects of Y69F mutations in homotetrameric R67 DHFR (9), 
mutation of symmetry related tyrosine 69 residues to non-conservative leucine residues 
also affects both ligand binding and catalysis.  As indicated in Table 1, the Km (NADPH) 
values are similar between Y69F and Y69L R67 DHFRs as are the Kd (NADPH) values 
shown in Table 2.  In contrast, the Km (DHF) value is ~2.5 fold weaker for Y69L as 
compared to Y69F R67 DHFR.  In addition, a clear reduction in kcat for Y69L R67 DHFR 
is observed as compared to both Y69F R67 DHFR and wild-type R67 DHFR.   
Circular dichroism studies, shown in Figure 3, were again performed to ensure 
that the Y69L mutations do not cause a large change in the protein structure.  Although 
changes in the CD signal for Y69L and wild-type R67 DHFRs are observed, these 
variations are similar to those observed previously for mutations in the homotetrameric 
enzyme and are likely due to local changes in structure brought about by the non-
conservative mutations (9). 
 Titrations of Y69L R67 DHFR with hydrochloric acid were also performed to 
ensure that the mutations do not affect the dimer-tetramer equilibrium that occurs upon 
protonation of symmetry-related histidine 62 residues (19, 20).  The Koverall value 
(defined as Kd2n/Ka) for Y69L R67 DHFR differs from that of the wild-type enzyme (data 
not shown) suggesting that mutations do have an affect on this equilibrium. 
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Discussion 
 This study investigates the role of Y69 in the binding and catalysis of R67 DHFR.  
Since specific contacts involving Y69 with the ligands have not been delineated by NMR 
and X-ray crystallography, a mutagenesis approach was used.  
Steady-state kinetic and isothermal titration calorimetry studies were performed 
on the various Y69F asymmetric mutants.  Previous studies suggest that R67 DHFR 
follows a random mechanism, but because of the interligand cooperativity patterns, 
NADPH binding followed by DHF binding is the preferred pathway (28).  Therefore, 
when possible, NADPH should bind the enzyme first and preferentially interact with the 
tightest binding site available.  This site, presumably, should contain the wild-type Y69 
residue(s).  DHF should bind next to the enzyme•NADPH complex and its pterin ring 
would be expected to stack with the nicotinamide ring of NADPH in the center of the 
pore.  The PABA-glutamic acid tail would then be forced to interact with the amino acid 
residue available at position 69, either wild-type or mutant, depending on the 
configuration. 
NADPH Binding Interactions in the Binary and Michaelis Complexes 
Comparisons of steady-state kinetic values for the asymmetric Y69F mutants 
suggest that for NADPH to display a wild-type Km value, two Y69 residues are required 
and these two residues must be located on the same side of the pore.  Only two of the 
Y69F asymmetric mutants meet this criterion:  Y69F: 1 and Y69F: 1+3.  For these 
mutants, NADPH likely continues to bind first and prefers the wild-type side of the pore, 
thus exhibiting a wild-type Km value as indicated in Table 1.  However, when one half of 
the pore contains one Y69 and one Y69F residue (Y69F: 1+2, Y69F: 1+4, and Y69F: 
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1+2+3), the Km for NADPH might be expected to be weaker if one Y69-NADPH 
interaction has been disrupted.  As shown in Table 1, the Km (NADPH) values for the Y69F: 
1+2 and Y69F: 1+4 mutants are increased 3 fold while the Km (NADPH) value for the Y69F: 
1+2+3 mutant is increased 5 fold.  This latter increase may be a kinetic effect due to 
interligand interactions between NADPH and DHF in the Michaelis complex as DHF 
presumably binds to the half pore possessing two Y69F mutations.  Finally, the Km 
(NADPH) value for Y69F: 1+2+3+4 continues to increase and mimics the Km (NADPH) for 
homotetrameric Y69F R67 DHFR.   
 Why is it necessary that both tyrosine 69 residues be located on one side of the 
pore for NADPH to bind with a wild-type Km?  One possibility is that two tyrosine 69 
residues located in different domains on the same side of the pore form interactions with 
NADPH.  Support for this proposal comes from a computational model of the ternary 
complex.  From this model, contacts are proposed between Y69 in monomer A of the 
homotetramer and the pyrophosphate bridge of NADPH as well as contacts between Y69 
in monomer D of the homotetramer and the adenine ribose of NADPH (3).  Monomer A 
corresponds to domain 1 of the Quad 3 construct while monomer D corresponds to 
domain 3.  As illustrated in Figure 1C, both of these residues have been mutated to 
phenylalanine residues in the Y69F: 1+3 mutant.  However, due to the symmetry of the 
protein, the same contacts proposed in the docking model can also occur between Y69 
residues in domains 2 and 4 and NADPH.    
Since a direct interaction(s) between the -OH of Y69 and NADPH was not 
predicted, either the ternary complex model requires revision or water mediated 
interactions could be occurring.  Alternatively, since the contacts predicted by DOCK 
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betweenY69 residues and NADPH largely involve the ring edge of the tyrosine residue 
(8), it is possible that a dipole-charge interaction(s) may be present (1/r2 distance 
dependence; (32)).  Since the phenylalanine sidechain lacks the -OH group of tyrosine, 
this dipole moment would be diminished in the Y69F mutant.  
Do the Kd data also support the model that suggests two Y69 residues are 
involved in NADPH binding?  In general, the Kd values for NADPH binding obtained by 
ITC correspond to the Km values and exhibit a similar trend in that the Kd values increase 
as the number of mutations is increased.  The ∆H values also become less negative as the 
number of mutations is increased.  If the Kd values were to exactly mimic the Km 
behavior, the Kd (NADPH) for the Y69F: 1+3 mutant should be wild-type and the Kd (NADPH) 
for the Y69F: 1+4 mutant would be weaker.  Instead, the Kd and ∆H values for the Y69F: 
1+4 mutant are more similar to Quad 3 values than those for the Y69F: 1+3 mutant.  
However, some differences may occur as these two techniques monitor different 
complexes, the Michaelis complex for steady-state kinetics and a binary complex where 
two NADPH molecules bind for isothermal titration calorimetry.  Since interactions 
between two NADPH molecules versus one DHF and one NADPH molecule are likely 
different, it is possible that these differences are reflected in the values obtained by the 
two techniques.   
DHF binding interactions in the binary and Michaelis complexes 
Interligand Overhauser effects suggest that NADPH and DHF bind on opposite 
halves of the pore, allowing only the rings of the ligands to interact at the pore’s center 
(6).  This model is supported by steady-state kinetics data for the Y69F: 1 and Y69F: 1+3 
mutants which suggest that NADPH interacts with the wild-type side of the pore, thus 
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forcing DHF to bind to the other half pore which contains a mutation(s).  Therefore for 
these mutants, a wild-type Km (NADPH) is observed coupled with a weaker Km (DHF) value.  
Also, similar Km (DHF) values are observed for the Y69F: 1+2 and Y69F: 1+4 mutants as 
both halves of the pore possess a mutation.  The Km (DHF) value for Y69F: 1+2+3 is 
weaker than that of the single and double mutants as the second half of the pore now 
contains two mutations.  The Km (DHF) for Y69F: 1+3 is tighter than expected since the 
half pore with which DHF is proposed to interact also has two mutated Y69 residues.  
However, previous studies suggest the importance of interligand interactions in ligand 
binding (28).  Specifically, positive cooperativity between enzyme bound NADPH and 
the second ligand, DHF, is proposed to facilitate binding of DHF (28).  Since NADPH is 
proposed to bind in a wild-type orientation in Y69F: 1+3 DHFR, it is possible that 
interligand interactions between bound NADPH and DHF partially account for the tighter  
Km (DHF) observed in this mutant.  
 Support for this model is also provided in the ternary complex model where folate 
was docked into a DHFR•NMNH complex.  (NMNH is a fragment of NADPH that 
contains only the nicotinamide ring, ribose ring, and a single phosphate group.)  From the 
docking studies, the highest scoring folate conformer is predicted to form a hydrogen 
bond between the –OH of Y69 (in monomer C which corresponds to domain 4 of Quad 
3) and the α-carboxylate of the folate tail.  However, other high scoring folate conformers 
are also predicted with alternate positions for the PABA-glutamic acid tail of DHF (13).  
Mobility in the tail region has additionally been observed in both X-ray crystallography 
and NMR studies (3, 6).  It is therefore possible that interactions occurring between Y69 
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and folate (or DHF) are weak and/or transient, hence, interligand interactions between 
enzyme bound NADPH and folate/DHF play an important role in DHF binding.  
   Do these trends continue in the DHF binary complex data?  Although we are 
unable to quantify differences in binding affinity of the Y69F symmetric mutants for 
DHF, we can draw qualitative conclusions based on variations in isotherm shape for the 
asymmetric mutants.  First, increasing the number of Y69F mutations weakens the 
binding affinity for DHF as increasing DHF concentrations are required to reach 
saturation.  Interestingly, as the number of Y69F mutations is increased, a more 
prominent hook is observed in the isotherms, suggesting changes in inter-ligand 
interactions between the two DHF molecules and/or different enthalpies associated with 
the two binding events. 
What role does Y69 play in catalysis? 
Mutation of tyr 69 to phe in R67 DHFR facilitates catalysis as the kcat value for 
the mutant reaction increases (9).  Comparison of the kcat values for Quad 3 and the 
Y69F: 1+2+3+4 mutant reveals an approximately 2 fold increase in the kcat upon addition 
of the mutations.  This increase is comparable to the increase observed in Y69F R67 
DHFR as compared to wild-type R67 DHFR.  That the kcat for the Y69F: 1+2+3+4 
mutant is less than that of Y69F R67 DHFR is not unreasonable since the kcat for Quad 3 
is also less than the kcat for wild-type R67 DHFR (11).  In addition, an increase in kcat is 
not observed until two Y69F mutations are present in the Y69F: 1+4 mutant.  The kcat 
values for the Y69F: 1+2+3 and Y69F: 1+2+3+4 mutants are similar to that of the Y69F: 
1+4 mutant indicating that increasing the number of Y69F mutations to 3 or 4 does not 
result in additional increases in kcat.  These three mutants are similar in that they each 
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contain two mutations along either the ceiling and/or floor of the active site pore.  It is 
therefore tempting to suggest that loss of interactions between these residues and 
NADPH and/or DHF facilitate the reaction.   
Based on steady-state kinetic analyses of Y69F R67 DHFR and the Y69F 
asymmetric mutant series, one possible role for Y69 is in ground-state binding.  This is 
supported by steady-state kinetic data where the Km values for NADPH and DHF binding 
are increased as the number of mutations is increased.  However, these data also suggest 
that in order to reach the transition state, it is necessary for at least one Y69 interaction to 
be disrupted.  This is supported by increasing kcat values as Y69 residues are mutated to 
phenylalanine in the Y69F: 1+4, Y69F: 1+2+3, and Y69F: 1+2+3+4 mutants.  These data 
continue to support the model (9) that Y69F mutations in the homotetramer destabilize 
binding in the ground state to a greater extent than binding in the transition state.  Further, 
the model can be extended such that the Y69F: 1+4 double mutant topology appears to 
provide the least perturbation to ground-state binding coupled with the best match to the 
transition state configuration.  
What types of interactions occur between the ligands and Y69? 
 Another goal of this mutagenesis series has been to determine the type(s) of 
interaction(s) that occur between Y69 and both NADPH and DHF.  We have approached 
this goal via site-directed mutagenesis of symmetry-related Y69 residues to both 
conservative and non-conservative amino acid residues.  With the exception of the Y69F 
enzyme variants, site-directed mutagenesis of Y69 to other amino acid residues has been 
complicated by trimethoprim sensitivity in cells containing the mutagenized plasmids.  
The importance of Y69 in catalysis is, therefore, emphasized in that most mutations at 
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this position are not tolerated without a loss of TMP resistance which usually correlates 
with large decreases in protein yield and/or kcat/Km.  
 Comparisons of the kinetic parameters observed for Y69F R67 DHFR, Y69L 
R67 DHFR, and wild-type R67 DHFR yield interesting information regarding the 
involvement of Y69 in both ligand binding and catalysis.  Analysis of Y69F R67 DHFR 
suggests the importance of tyrosine’s hydroxyl group as its removal results in a 20 fold 
increase in Km (NADPH) and a 10 fold increase in Km (DHF) (9).  Hence, the hydroxyl group is 
necessary for binding interactions with NADPH and DHF.  However, removal of the 
hydroxyl group appears to facilitate catalysis as the kcat for Y69F R67 DHFR is increased 
~ 2 fold in comparison to the wild-type enzyme (9).  Similar to Y69F R67 DHFR, the 
steady state kinetic parameters are also affected in Y69L R67 DHFR.  The Km (DHF) for 
Y69L R67 DHFR is > 20 fold weaker than the Km (DHF) for wild-type R67 DHFR and is 
~2.5 fold greater than the Km (DHF) for Y69F R67 DHFR suggesting that the aromatic ring 
of Y69 as well as the hydroxyl group are important for interactions with DHF.  Although 
the Km (NADPH) is also increased in Y69L R67 DHFR as compared to the wild-type 
enzyme, the value is similar to that obtained for Y69F R67 DHFR suggesting that the 
hydroxyl moiety is most important for interactions with NADPH.  This is supported by 
the similar Kd values obtained for NADPH binding to Y69L R67 DHFR and Y69F R67 
DHFR.  The aromatic ring also appears to play an important role in catalysis as is 
evidenced by the 4 fold decrease in kcat in Y69L R67 DHFR.  Whether the hydroxyl and 
aromatic regions of tyrosine 69 are directly involved in interactions with both DHF and 
NADPH or are mediated through water is not clear.  Direct assessment of the type of 
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interaction afforded by tyrosine 69 and the ligands requires more structural based studies 
such as NMR and x-ray crystallography, which are currently in progress.     
What general trends are observed for Quad 3 asymmetric mutants? 
  We have previously constructed asymmetric mutant series involving Q67H (1) as 
well as K32M substitutions (Hicks et al., manuscript in preparation).  From these studies, 
as well as the present experiments, several general trends are noted.  (K32, Q67, I68 and 
Y69 have been identified as the most important residues in binding and catalysis from a 
series of site directed mutagenesis experiments probing the residues in the active site pore 
((2, 9), Strader et al., manuscript submitted,).  The first pattern finds the single 
asymmetric mutant behaves similarly to Quad 3, indicating a single mutation is well 
tolerated.  Conversely, to produce a substantial effect and begin to mimic the mutation in 
a homotetrameric context, three mutations are usually required. (This could not be 
accomplished with the K32M asymmetric mutants as this mutation affects the dimer-
dimer interface, hence only single and double K32M mutants were constructed (Hicks et 
al., manuscript submitted)).  Second, the 1+2 and 1+4 double mutants (Y69F and K32M 
series) show similar steady state kinetic behavior.  For these mutants, an initial 
expectation was that if the docked model for the ternary complex described how the 
molecules were arranged in the ground state, then minimal effects on kcat and Km would 
be expected for the asymmetric mutant that matches this predicted, productive topology 
(1+2), with larger effects on the non-preferred topology (1+4).  However the observed 
similar kinetic behavior for the 1+2 and 1+4 mutants indicates that both topologies allow 
comparable interactions with the PABA-glutamic acid tail of DHF.  This behavior 
correlates with the disorder observed for the glutamate tail of bound folate in the crystal 
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structure (6) as well as NMR studies that find the glu tail is mobile (3).  Further, docking 
of DHF into an R67 DHFR•NMNH complex predicts various orientations for the p-
aminobenzoic acid (PABA)-glu tail (13).   
A third, general pattern observed for the K32M and Y69F asymmetric mutant 
series is that the 1+3 double mutants show minimal perturbation of NADPH binding.  
This pattern supports initial binding of NADPH into the “wild type half-pore” followed 
by DHF being forced to bind in the “mutant side.”  Consequently greater effects on DHF 
binding are observed in these mutants.  Fourth, mutations at the center of the pore 
(Q67H) produce different effects than mutations further out on the pore surface (K32M 
and Y69F).  For example, the Q67H mutations are associated with tighter binding of all 
complexes and result in severe NADPH and DHF inhibition.  This observation is 
consistent with the crystallographic R67 DHFR•folate•folate binary complex and the 
docked ternary complex model that point to the hourglass center of the pore being 
associated with ring stacking and helping to establish interligand cooperativity patterns.  
In contrast, mutations further out the pore surface do not display substrate/cofactor 
inhibition, but rather are most consistent with alternative binding modes associated with 
the DHF tail being tolerated.    
To conclude, these trends all support the general model whereby NADPH and 
folate enter the active site pore from either end, meeting at the center where catalysis 
occurs.   NADPH likely binds first, with a preference for the least perturbed side of the 
pore.  The nicotinamide ring then provides an interaction surface for binding the pteridine 
ring of DHF.  A “one site fits both” strategy must be employed because the homotetramer 
possesses only a single active site pore coupled with the need to bind two ligands.  This 
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“catch-22” situation appears to lead to symmetry related residues that aid ligand binding, 
but provide too much ground state stabilization.  To reach the transition state, some of 
these interactions likely need to break.  Thus construction of asymmetric mutants has 
begun to provide clues to unravel how R67 DHFR works as an enzyme.  
Acknowledgements 
Authors thank Jun Wu for purification of Y69L R67 DHFR and preliminary steady-state 
kinetic experiments and Dr. Cynthia Peterson for review of this manuscript. 
 
 
 
 
 
 
 
 
 
 123
References 
1. Matthews, C. K., and van Holde, K. E. (1996) Biochemistry, The 
Benjamin/Cummings Publishing Company, Inc., New York. 
2. Stone, D., and Smith, S. L. (1979) J Biol Chem 254, 10857-10861. 
3. Narayana, N., Matthews, D. A., Howell, E. E., and Nguyen-huu, X. (1995) Nat 
Struct Biol 2, 1018-1025. 
4. Matthews, D. A., Smith, S. L., Baccanari, D. P., Burchall, J. J., Oatley, S. J., and 
Kraut, J. (1986) Biochemistry 25, 4194-4204. 
5. Brito, R. M., Reddick, R., Bennett, G. N., Rudolph, F. B., and Rosevear, P. R. 
(1990) Biochemistry 29, 9825-9831. 
6. Li, D., Levy, L. A., Gabel, S. A., Lebetkin, M. S., DeRose, E. F., Wall, M. J., 
Howell, E. E., and London, R. E. (2001) Biochemistry 40, 4242-4252. 
7. Pitcher, W. H., 3rd, DeRose, E. F., Mueller, G. A., Howell, E. E., and London, R. 
E. (2003) Biochemistry 42, 11150-11160. 
8. Hicks, S. N., Smiley, R. D., Hamilton, J. B., and Howell, E. E. (2003) 
Biochemistry 42, 10569-10578. 
9. Strader, M. B., Smiley, R. D., Stinnett, L. G., VerBerkmoes, N. C., and Howell, 
E. E. (2001) Biochemistry 40, 11344-11352. 
10. Park, H., Bradrick, T. D., and Howell, E. E. (1997) Protein Eng 10, 1415-1424. 
11. Smiley, R. D., Stinnett, L. G., Saxton, A. M., and Howell, E. E. (2002) 
Biochemistry 41, 15664-15675. 
12. Bradrick, T. D., Shattuck, C., Strader, M. B., Wicker, C., Eisenstein, E., and 
Howell, E. E. (1996) J Biol Chem 271, 28031-28037. 
 124
13. Howell, E. E., Shukla, U., Hicks, S. N., Smiley, R. D., Kuhn, L. A., and 
Zavodszky, M. I. (2001) J Comput Aided Mol Des 15, 1035-1052. 
14. Strader, M. B., and Howell, E. E. (1997) Gibco-BRL Focus 19, 24-25. 
15. Tartof, K. D., and Hobbs, C.A. (1987) BRL Focus 9, 12. 
16. de Bernandez Clark, E., Schwartz, E., and Rudolph, R. (1999) Methods Enzymol. 
309, 217-235. 
17. Gornall, A. G., Bardawill, C.J., and David, M. M. (1949) Journal of Biological 
Chemistry 177, 751-766. 
18. Segel, I. H. (1975) Enzyme Kinetics, John WIley & Sons, Inc., New York. 
19. Park, H., Zhuang, P., Nichols, R., and Howell, E. E. (1997) J Biol Chem 272, 
2252-2258. 
20. Nichols, R., Weaver, C. D., Eisenstein, E., Blakley, R. L., Appleman, J., Huang, 
T. H., Huang, F. Y., and Howell, E. E. (1993) Biochemistry 32, 1695-1706. 
21. West, F. W., Seo, H. S., Bradrick, T. D., and Howell, E. E. (2000) Biochemistry 
39, 3678-3689. 
22. Fersht, A. (1999) Structure and Mechanism in Protein Science, W.H. Freeman 
and Company, New York. 
23. Reece, L. J., Nichols, R., Ogden, R. C., and Howell, E. E. (1991) Biochemistry 
30, 10895-10904. 
24. Kuntz, I. D., Blaney, J. M., Oatley, S. J., Langridge, R., and Ferrin, T. E. (1982) J. 
Mol. Biol. 161, 269-288. 
25. Shoichet, B. K., and Kuntz, I. D. (1993) Protein Eng 6, 723-732. 
 125
 126
26. Wiseman, T., Williston, S., Brandts, J.F., and Lin, L.N. (1989) Analytical 
Biochemistry 179, 131-137. 
27. Leavitt, S., and Freire, E. (2001) Current Opinion in Structural Biology 11, 560-
566. 
28. Bradrick, T. D., Beechem, J. M., and Howell, E. E. (1996) Biochemistry 35, 
11414-11424. 
29. Poe, M. (1973) Journal of Biological Chemistry 248, 7025-7032. 
30. Khaled, M. A., and Krumdieck, C. L. (1985) Biochem Biophys Res Commun 130, 
1273-1280. 
31. Woody, R. W. (1995) Methods of Enzymology 246, 34-71. 
32. Burley, S. K., and Petsko, G. A. (1988) Adv Prot Chem 39, 125-189. 
 
  
 
 
 
 
 
 
 
 
Part IV:  R67 DHFR and Quad 3 DHFR, A Global Perspective 
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Catalytic Efficiency 
R67 dihydrofolate reductase provides a unique approach to catalysis as a 25Å 
pore serves as the binding site for both ligands, DHF and NADPH (2).  Compared to 
other enzymes, however, R67 DHFR is rather inefficient.  Enzyme efficiency is defined 
by kcat/Km.  For the most efficient enzymes, such as acetylcholinesterase, the kcat/Km 
values are on the order of 108 s-1M-1(3).  In these enzymes, the rate-determining step for 
the reaction approximates the rate of encounter of the enzyme and substrate which is 
diffusion-limited (3).  In contrast, lower kcat/Km(NADPH) and kcat/Km(DHF) values of 1.8•105s-
1M-1and 1.2•105 s-1M-1, respectively are observed for R67 DHFR, yielding a less efficient 
enzyme (4).   
One of the goals of asymmetrically mutating R67 DHFR has been to artificially 
generate a more efficient enzyme (5).  This goal was first approached by generating 
asymmetric Q67H mutants (1).  Interestingly, Q67H R67 DHFR is a more efficient 
enzyme than wild-type R67 DHFR as its kcat/Km(NADPH) value is 10 fold greater than the 
wild-type enzyme, while the kcat/Km(DHF) value is also slightly increased (1.2 fold) (5).  
The increase in catalytic efficiency for the Q67H R67 DHFR mutant is largely due to the 
increase in binding affinity for both NADPH and DHF (~200 and ~40 fold, respectively) 
as the kcat for the reaction actually decreases ~50 fold (5).  With this increase in binding 
affinity, however, an increase in non-productive binding is observed for Q67H R67 
DHFR where both substrate and cofactor become inhibitory (5).  Therefore, our goal in 
generating the asymmetric Q67H mutants was to generate an efficient enzyme which 
maintains tight binding but disfavors formation of inhibitory complexes (1, 5).   
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Table 1 compares the kcat/Km values for the Q67H asymmetric mutants.  As 
indicated in the table, none of the kcat/Km values for the asymmetric mutants is increased 
greater than that of the Q67H: 1+2+3+4 asymmetric mutant which corresponds to Q67H 
R67 DHFR, except the kcat/Km(NADPH) value for the Q67H:1+2 mutant which is increased 
~2 fold compared to the quadruple mutant.  The binding and catalysis constants for the 
Q67H: 1+2+3+4 mutant are similar to those for Q67H R67 DHFR (1).  Unfortunately, 
rather noticeable inhibition, similar to that observed for Q67H R67 DHFR, is also 
observed for this mutant.  Although the Q67H: 1+2 mutant also has an obvious increase 
in the kcat/Km(NADPH), cofactor inhibition is noticeable in this mutant as well.  The only 
Q67H asymmetric mutants which lack clear substrate and/or cofactor inhibition are the 
Q67H: 1 and Q67H: 1+4 mutants (1).  However, the catalytic efficiency of these mutants 
is not increased relative to the Quad 3 control.  In fact, the kcat/Km(DHF) values are actually 
decreased ~ 2 fold.  We were, therefore, unable to engineer a more efficient enzyme 
lacking substrate and cofactor inhibition with this series of asymmetric mutants.    
 One issue associated with the Q67H asymmetric mutants is the location of Q67 
residues in the center of the active site pore (1).  These residues form the “ceiling” and 
“floor” of the pore as they form hydrogen bonds with their symmetry related residues 
across the dimer-dimer interface of the enzyme (2).  We, therefore, proposed that 
introduction of histidine residues asymmetrically at these locations may affect local 
packing interactions as the hydrogen bonding network may be disrupted when one 
histidine is introduced along the dimer-dimer interface (i.e. in the Q67H: 1+3 mutant) (1).  
This problem diminishes when the mutated residues occur further from the center of 
symmetry.  As shown in Figure 1, symmetry related tyrosine 69 residues occur further  
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Table 1.  Comparison of catalytic efficiencies for Q67H, Y69F, and K32M asymmetric 
mutants of Quad 3 DHFR. 
 
Complex kcat/Km(NADPH) 
(s-1M-1) 
kcat/Km(DHF) 
(s-1M-1) 
Quad3 DHFRa 1.8*105  1.2*105 
 
Q67H: 1 DHFRb 1.8*105 6.0*104 
 
Q67H: 1+2 DHFRb 7.5*105 6.0*104 
Q67H: 1+3 DHFRb 1.3*105 2.0*104 
Q67H: 1+4 DHFRb 1.6*105 6.0*104 
Q67H: 1+2+3 DHFRb 
 
2.0*105 1.0*104 
Q67H: 1+2+3+4 DHFRb 3.8*106 7.7*105 
Y69F: 1 DHFRc 1.5*105 5.0*104 
Y69F: 1+2 DHFRc 7.0*104 5.0*104 
Y69F: 1+3 DHFRc 1.8*105 3.0*104 
Y69F: 1+4 DHFRc 1.4*105 7.0*104 
Y69F: 1+2+3 DHFRc 
 
7.0*104 4.0*104 
Y69F: 1+2+3+4 DHFRc 4.0*104 3.0*104 
K32M: 1 DHFRa 1.6*105 9.0*104 
K32M: 1+2 DHFRa 1.0*104 7.0*104 
K32M: 1+3 DHFRa 2.0*104 1.0*104 
K32M: 1+4 DHFRa 2.0*104 1.0*104 
a Taken from (Hicks et al., manuscript in preparation). 
b Taken from (1). 
c Taken from (Stinnett et al., manuscript in preparation). 
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Figure 1.  Ribbon diagram of R67 DHFR (protein data bank 1VIE) with Y69 residues 
shown as purple balls-and-sticks, while Q67 residues are shown as white balls-and-
sticks.  Monomer 1 is green, while monomers 2, 3, and 4 are yellow, pink, and cyan, 
respectively.    
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from the center of symmetry than symmetry related glutamine 67 residues.  The tyrosine 
69 residues are also sufficiently separated that they are unable to hydrogen bond with 
their symmetry related partners (2, 6).  In addition, the kcat for the Y69F R67 DHFR 
mutant is increased ~2 fold in respect to the wild-type enzyme while the Km(NADPH) and 
Km(DHF) values are increased ~15 and ~10 fold, respectively (6).  It was, therefore, 
possible that a more efficient enzyme could be generated in the Y69F asymmetric mutant 
series where the kcat for the reaction is increased but the Km values are unaffected.          
Catalytic efficiencies for each of the Y69F asymmetric mutants are outlined in 
Table 1.  None of the kcat/Km values for these mutants is increased relative to the Quad 3 
control.  In fact, in most cases, these mutants are less efficient than the Quad 3 control.  
This is likely due to the disparate effects of the mutations on both the kcat and Km values.  
For example, the Y69F: 1 and Y69F: 1+3 mutants are the only mutants where the 
Km(NADPH) values are unaffected.  However, for these mutants, the kcat values are also 
affected minimally (Stinnett et al., manuscript in preparation).  Hence, the kcat/Km(NADPH) 
values for these mutants are similar to the Quad 3 control.  In addition, the Km(DHF) values 
for the remainder of the asymmetric Y69F  mutants are weakened in respect to the Quad 
3 control, thus resulting in lower kcat/Km(DHF) values (Stinnett et al., manuscript in 
preparation).  Although it was proposed that a more efficient enzyme could be generated 
where the Km values were unaffected and the kcat values were increased, for the Y69F 
asymmetric mutant series, an increase in kcat was observed only when Km values were 
also increased (Stinnett et al., manuscript in preparation).  Therefore, none of the Y69F 
asymmetric mutants were more efficient enzymes than the Quad 3 control. 
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Asymmetric mutants of symmetry related K32 residues have also been generated 
and analyzed (Hicks et al., manuscript in preparation).  Similar to Y69, K32 residues are 
also located further away from the center of symmetry of the active site (2).  In contrast 
to Y69, however, mutation of K32 residues to methionine residues in the homotetrameric 
enzyme results in a dimeric form of the enzyme (7).  Since docking studies suggest that 
these residues interact with both ligands of R67 DHFR (8), an alternate approach 
involving salt effects was employed to determine the role of these residues in ligand 
binding and catalysis (7). 
Lysine residues, being positively charged in water at pH values around neutrality, 
are capable of forming ionic contacts with negatively charged ligands which include the 
ligands for DHFR.  Therefore, it is possible for lysine 32 residues to interact with both 
NADPH and DHF electrostatically.  Since mutagenesis of K32 residues to non-polar 
methionine residues affects the stability of the enzyme, the interactions between K32 
residues and the ligands were evaluated by adding increasing concentrations of salt into 
the reaction solution.  From these studies, it was determined that symmetry related K32 
residues are involved in interactions with both NADPH and DHF (7). 
Similar to studies of Y69F R67 DHFR, disruption of electrostatic interactions 
between symmetry related K32 residues and the substrate and cofactor yields an 
increased rate of catalysis for the reaction while resulting in weaker Km values for both 
ligands (7).  Therefore, generation of a more efficient enzyme could again be possible by 
building asymmetric K32M mutants where the Km values are minimally perturbed but kcat 
is increased.  In addition, it was proposed that adding only one or two K32M mutations to 
the enzyme would be less destabilizing than adding all four mutations to the enzyme (as 
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occurs in K32M R67 DHFR).  Therefore, the following K32M asymmetric mutants were 
generated and analyzed:  K32M: 1, K32M: 1+2, K32M: 1+3, and K32M: 1+4 (Hicks et 
al., manuscript in preparation). 
The catalytic efficiencies of each of the K32M asymmetric mutants are shown in 
Table 1.  The kcat/Km values for the K32M: 1 mutant are similar to Quad 3 as would be 
expected since the kcat and Km values are affected minimally in this mutant (Hicks et al., 
manuscript in preparation).  Each of the kcat/Km values for the double mutants is 
decreased with respect to Quad 3.  However, the cause of this decrease differs for the 
K32M: 1+2 and K32M: 1+4 mutants as compared to the K32M: 1+3 mutant.  For the 
K32M: 1+2 and K32M: 1+4 mutants, the decrease in kcat/Km values is largely related to 
the effect of these mutations on kcat (Hicks et al., manuscript in preparation).  For both 
mutants, the rate of the reaction is slower, while the Km values are either not affected or 
are increased no more than four-fold (Hicks et al., manuscript in preparation).  These 
effects combine to yield decreases in kcat/Km.  In contrast, the rate of catalysis for the 
K32M: 1+3 mutant is increased ~ 4.5 fold.  However, the Km values for NADPH and 
DHF are increased ~ 35 fold and ~50 fold, respectively.  Although an increase in kcat is 
observed, greater increases in the Km values result in decreases in kcat/Km.  Again, in no 
K32M asymmetric mutant was the catalytic efficiency increased as none of the mutations 
resulted in increasing kcat values with minimal effects on Km (Hicks et al., manuscript in 
preparation).   
Interestingly, none of our mutagenesis strategies, including mutations in the 
homotetramer and asymmetric mutations, has generated a more efficient enzyme that 
does not also yield substrate and cofactor inhibition.  Is it possible that this enzyme is 
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optimized for the greatest possible efficiency without substrate and cofactor inhibition?  
While this possibility exists, we have yet to test the effects of generating asymmetric 
mutants which contain different amino acid mutations such as asymmetric mutants 
containing both Q67H and Y69F or Q67H and K32M mutations.   
Why generate mutants with both Q67H and Y69F or K32M asymmetric 
mutations?  Q67H asymmetric mutations result in decreases in Km values and kcat values 
(1), while certain Y69F asymmetric mutations result in increases in Km and kcat values 
(Stinnett et al., manuscript in preparation) as does the K32M: 1+3 mutant (Hicks et al., 
manuscript in preparation).  It is therefore possible that building an asymmetric mutant 
containing both Q67H and Y69F or K32M mutations may result in decreased Km values 
and an increase in kcat values yielding a more efficient enzyme.    
Of the possible Y69F/Q67H asymmetric mutant combinations, which 
combination would likely result in the most efficient enzyme which is not inhibited at 
high concentrations of substrate and cofactor?  In order to approach this question, it is 
first necessary to understand which mutations result in tighter Km values and which 
facilitate kcat.  A single Q67H mutation results in an ~ 4 fold decrease in kcat with little 
affect on the Km values.  This effect may be related to disruption of hydrogen bonding 
interactions between symmetry-related Q67 residues which could affect local packing 
interactions (1).  To minimize this possibility, both glutamine residues along one dimer-
dimer interface should be mutated to histidine residues.  This occurs in the Q67H: 1+4 
mutant.  For this mutant, the Km(NADPH) is ~4.5 fold tighter than the Quad 3 control while 
the Km(DHF) is only ~ 2.5 fold tighter than the Quad 3 control.  In addition, no noticeable 
DHF or NADPH inhibition is observed for this mutant making it an ideal template on 
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which to add Y69F mutations (1).  Of the Y69F double mutants, only one results in a 
noticeable increase in kcat for the reaction, the Y69F: 1+4 mutant.  This mutant contains 
two Y69F mutations, both located along the “floor” of the active site.  It was therefore 
proposed that mutation of two Y69 residues along the dimer-dimer interface may 
facilitate transition state binding (Stinnett et al., manuscript in preparation).  The 
Km(NADPH) and Km(DHF) values for this mutant are increased ~2.5 fold and ~ 4 fold, 
respectively, while the kcat is increased ~ 2 fold (Stinnett et al., manuscript in 
preparation).  Based on this information, we propose that the combination of Y69F: 
1+4/Q67H: 1+4 mutations may result in a more efficient enzyme (compared to the Quad 
3 control) as the Q67H mutations will drive tighter binding and the Y69F mutations will 
facilitate catalysis.  We also expect that this mutant will not be inhibited at high 
concentrations of substrate and cofactor as the Q67H: 1+4 mutation and the Y69F: 1+4 
mutation do not cause noticeable DHF and NADPH inhibition ((1), Stinnett et al., 
manuscript in preparation). 
What K32M/Q67H asymmetric combinations may increase catalytic efficiency?  
In this case, we propose use of the Q67H: 1+2+3+4 mutant as a template as the Km(NADPH) 
and Km(DHF) values for this mutant are ~ 170 and ~ 50 fold tighter, respectively, than 
those of the Quad 3 control (1).  Of the possible K32M asymmetric mutants, we propose 
addition of K32M mutations to domains 1 and 3 of the Q67H: 1+2+3+4 template.  These 
mutations are chosen as they include the only K32M asymmetric mutations which result 
in an increase in kcat for the reaction (Hicks et al., manuscript in preparation).  For the 
Q67H: 1+2+3+4/K32M: 1+3 mutant, we expect that NADPH will bind first to the 
enzyme and its nicotinamide ring will interact with the Q67H residues along either the 
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“floor” or “ceiling” of the active site.  The tail of NADPH will interact with wild-type 
K32 residues (in domains 2 and 4) on one half of the enzyme.  DHF will bind following 
NADPH and interact with both the nicotiname ring (through interligand contacts) and the 
residues available on the opposite side of the pore, specifically with the Q67H residues 
located on the “floor” or “ceiling” (which are not tied up forming contacts with NADPH).  
The kcat for the reaction will be increased as these studies suggest that a K32 interaction 
with DHF must be disrupted to approach the transition state, and this requirement is 
fulfilled in the K32M: 1+3 mutant where no wild-type K32 residues are available to 
interact with DHF (Hicks et al., manuscript in preparation).  Therefore, we propose that 
generation of a Q67H: 1+2+3+4/K32M: 1+3 mutant may yield an increase in catalytic 
efficiency as the Q67H mutations will drive tight binding through ring stacking 
interactions while the K32M mutations will facilitate catalysis.  Some inhibition, 
however, is possible in this construct as noticeable inhibition is observed for the Q67H: 
1+2+3+4 mutant (1, 5).        
Ligand Specificity 
In addition to attempts at generating a more efficient enzyme, another goal of 
building asymmetric mutants is to engineer specificity into the active site such that 
NADPH and DHF each bind at a specific location rather than having the option of 
interacting at four positions (1).  Steady-state kinetic analyses of certain Y69F (Stinnett et 
al., manuscript in preparation) and K32M (Hicks et al., manuscript submitted) 
asymmetric mutants suggest that this has been accomplished for NADPH.  For the Y69F: 
1 and Y69F: 1+3 mutants, a wild-type Km(NADPH) value is observed while a weaker 
Km(DHF) occurs (Stinnett et al., manuscript in preparation).  In addition, the Kd(NADPH) for 
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the K32M: 1 and K32M: 1+3 mutants is affected to a lesser extent by the mutations than 
the K32M: 1+2 and K32M: 1+4 mutants (Hicks et al., manuscript in preparation).  These 
data suggest that NADPH interacts first with the enzyme preferentially forming contacts 
with the wild-type side of the pore.  DHF then interacts with the residues available on the 
other side of the pore (Stinnett et al., manuscript in preparation, Hicks et al., manuscript 
in preparation).  This is supported by the Q67H asymmetric mutant studies.  In these 
studies, four Q67H mutations were necessary to yield a greater than 3 fold decrease in the 
Km(DHF) value (1).   
Although evidence suggests that NADPH binding specificity has been engineered 
into the enzyme through generation of certain asymmetric Y69F and K32M mutants, 
DHF specificity has not been achieved as DHF interacts with the site available following 
NAPDH binding.  Weaker Km(DHF) values have therefore been observed as DHF is 
required to interact with a least one mutant residue on the opposite side of the active site 
pore (Stinnett et al., manuscript in preparation, Hicks et al., manuscript in preparation).  
How then can DHF specificity be engineered into R67 DHFR?  Can we “rescue” DHF 
binding by engineering the opposite side of the pore with residues that will drive DHF 
binding.   
One possible means to generate DHF specificity is to again build asymmetric 
mutants which contain mutations of different amino acid residues such as K32 and Y69. 
Structural based studies, including NMR and x-ray crystallography, as well as docking 
studies, predict mobility of the glutamic acid tail of DHF/folate (2, 8, 9).  In addition, 
studies involving asymmetric K32M (Hicks et al., manuscript in preparation) and Y69F 
(Stinnett et al., manuscript in preparation) mutants suggest that interactions between these 
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residues on one side of the pore are weak allowing mobility of the tail between both 
domains.  One means to provide greater specificity for DHF would therefore be to 
provide additional contacts for the DHF tail on a single domain of one half of the active 
site limiting mobility of the tail region.  Several studies also suggest that NADPH may 
participate in DHF binding through interligand interactions (9, 10).  Thus, optimal DHF 
binding would be provided by tight binding of the nicotinamide ring of NADPH which, 
through interligand interactions, may tighten DHF binding.  In addition, specificity for 
DHF binding may be generated by providing additional contacts to the tail of DHF. 
What asymmetric mutations could tighten NADPH binding and through 
interligand contacts tighten DHF binding while providing contacts with the tail of DHF to 
limit its mobility?  The Q67H: 1+4 mutant provides a tighter binding site for NADPH 
which likely tightens DHF binding through interligand interactions (1).  Therefore, this 
mutant may provide a template for addition of other mutations to provide specificity for 
DHF (1).  Additional mutations must be built into this construct which preferentially 
provide contacts with the tail of DHF in contrast to the tail of NADPH.  Mutation of a 
Y69 residue to a lysine residue may provide such a contact.  Docking studies suggest that 
a hydrogen bond may form between the hydroxyl group of tyrosine 69 in domain 4 and 
the glutamate tail of DHF (8) which could, in theory, be replaced by ionic interactions 
between a lysine residue and the glutamate tail.  However, most contacts proposed 
between Y69 and NADPH are through the ring edge of tyrosine (8).  Mutation of the 
residue to lysine would result in disruption of these interactions.  Therefore, a Q67H: 
1+4/Y69K: 4 mutant could provide tight binding of NADPH through ring stacking 
interactions between the histidine residues and the nicotinamide ring.  Interligand 
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interactions between NADPH and DHF would facilitate DHF binding.  In addition, the 
tail of DHF should interact preferentially with the Y69K residue in domain 4 thereby 
limiting its mobility and rendering greater affinity.  The tail of NADPH would be 
disfavored from interacting with this residue as it lacks the ring edge dipolar contacts 
provided by the tyrosine residue (Stinnett et al., manuscript in preparation). 
Selection of the Productive Ternary Complex 
Another aspect of ligand binding in R67 DHFR that has become apparent through 
studies of these asymmetric mutants is the ability or inability of certain mutants to select 
for the productive ternary complex over the non-productive 2NADPH/2DHF binding 
modes.  Of the asymmetric mutants that have been analyzed, one series of mutants is 
particularly limited in its ability to select for the productive ternary complex, the Q67H 
series (1).  While moderate to severe substrate and/or cofactor inhibition is observed for 
most of the Q67H asymmetric mutants (1), no DHF and/or NADPH inhibition has been 
observed for any of the other asymmetric mutants (Stinnett et al., manuscript in 
preparation, Hicks et al., manuscript in preparation).  What characteristics of these 
mutants render them unable to select for the productive ternary complex?   
In contrast to Y69 and K32, Q67 residues are located in the center of the active 
site pore (2) allowing them to form contacts with the pteridine ring of DHF (2) and the 
nicotinamide ring of NADPH (9) which are also proposed to interact in the pore’s center.  
Mutation of these residues to histidine residues tightens binding for each ligand of R67 
DHFR (1, 5).  It has been suggested that this increase in binding affinity is related to 
stacking interactions between the rings of symmetry related histidine side chains and both 
the pteridine and nicotinamide rings (1, 5).  Structural evidence also suggests that the 
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NADPH and DHF tails are pointed away from the center of the enzyme’s active site.  
Thus, interligand interactions between DHF and NADPH occur mainly between the 
pteridine and nicotinamide rings.  Q67H mutations increase the binding affinity for both 
DHF and NADPH (9).  This increase in binding affinity likely alters the interligand 
cooperativity patterns between the 2DHF and 2NADPH non-productive binding modes in 
addition to the interligand interactions between the productive binding mode. 
Specifically, the productive binding mode has been altered in these mutants as the kcat for 
the reaction decreases as the number of mutations is increased.  This suggests that the 
nicotinamide and/or pteridine ring orientations are altered to some extent in these mutants 
as a result of ring stacking interactions.  As the rings must be juxtaposed in an optimal 
orientation for hydride transfer, it is likely that interactions with the histidine residues 
alter this juxtaposition (1).  It has been proposed that the nicotinamide and pteridine rings 
of R67 DHF are likely oriented in an endo conformation in the transition state (9).  These 
ring stacking interactions likely hinder formation of the endo transition state thus causing 
a decrease in the kcat for the reaction (1).   
What prevents Y69 and K32 mutations from displaying substrate and/or cofactor 
inhibition?  First, no such inhibition is observed in the wild-type enzyme (4).  Second, 
mutations of both of these residues weaken rather than tighten interactions with NADPH 
and DHF ((11), Stinnett et al., manuscript in preparation, Hicks et al., manuscript in 
preparation).  Third, these residues are located less near the center of the active site (2) 
and as such primarily interact with the tail regions of NADPH and DHF (8).  As 
interligand interactions occur mainly between the pteridine and nicotinamide rings (9), 
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Y69 and K32 residues have only an indirect affect on these interactions as they form 
contacts with only the tail regions of the molecules (8).  
Quad 3 as a Template for Understanding Ligand Binding and Catalysis in R67 DHFR 
 The Quad 3 construct has proved valuable in gaining insight into ligand binding 
and catalysis in R67 DHFR.  With this construct, we have been able to control the 
number and location of specific mutations within the active site and determine the effects 
of these mutations (1).  Analyses of the asymmetric Y69F and K32M mutants have 
provided support for a model in which residues on one side of the pore, consisting of 2 
domains (or monomers in the wild-type enzyme), form contacts with NADPH (Stinnett et 
al., manuscript in preparation, Hicks et al., manuscript in preparation).  In addition, 
results from the Y69F, K32M, and Q67H asymmetric mutant studies support a model 
(10) in which catalysis follows a preferred pathway where NADPH interacts with the 
enzyme first allowing it to form contacts with the tightest binding site available and 
allowing DHF bind to the enzyme-NADPH complex.  These studies have also pointed to 
the importance of interligand interactions in DHF binding (Stinnett et al., manuscript in 
preparation, Hicks et al., manuscript in preparation, (1)).  Finally, the Q67H: 1+4 mutant 
will likely prove valuable as a template for engineering asymmetric mutations as its 
binding affinity towards NADPH is increased in the absence of noticeable DHF and/or 
NADPH inhibition (1).   
R67 DHFR as a Template for “Evolving” an Enzyme Active Site 
 Our goal in these research projects has been to determine the mechanisms of 
ligand binding and catalysis in R67 DHFR.  Our approach has therefore been to perform 
site-directed mutagenesis studies that will provide a better understanding of the R67 
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DHFR catalyzed reaction.  However, these studies have largely focused on understanding 
the R67 DHFR reaction and its mechanisms involved in catalysis.  How, then, can we 
broaden the scope of our research to gain a better understanding of enzyme catalysis in 
general using R67 DHFR as a template? 
 Based on the understanding we have gained regarding the R67 DHFR catalyzed 
reaction using several biochemical and biophysical approaches, we propose R67 DHFR 
as an ideal template for “evolving” or modifying an enzyme’s active site.  Penning and 
Jez (12) review the methodologies commonly used to modify or alter enzyme active sites. 
In general, there are two approaches to this objective.  The first, enzyme redesign, is also 
referred to as a “rational” approach as specific mutations are generated in the enzyme 
active site which are expected to yield predicted results.  For redesigning an active site, 
structural information is critical in order to be able to predict the effects of specific 
mutations.  Two different types of redesign are common, site-directed mutagenesis and 
domain switching.  In the former, single amino acid residues are mutated while in the 
latter, an entire domain of the enzyme is changed.  The second approach, directed 
evolution, is “irrational” as random mutants of the active sites are generated and selected 
on the basis of their having a particular characteristic or function.  In contrast to enzyme 
redesign, directed evolution does not require extensive structural information since 
mutations are added randomly.  One common means of directed evolution is phage 
display.   
 Penning and Jez (12) review the use of enzyme redesign and directed evolution to 
approach five questions involving ligand binding and catalysis which include the 
following.  (1) Can an enzyme’s preference for substrate be changed with minimal effects 
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on catalytic efficiency using the same mechanism?  (2) Can an enzyme be designed to 
recognize a cofactor other than its natural cofactor?  (3) Can the stereochemistry of an 
enzyme’s ligands be altered?  (4) Can an enzyme catalyze a reaction other than its natural 
reaction?  (5) Can a protein be engineered such that it is able to catalyze a reaction?  Our 
discussion will focus on answering three of the questions using R67 DHFR as question 3 
is not straightforward without additional structural information and question 5 is not 
applicable.  For the purposes of this dissertation, we will focus only on redesign. 
 The first question that can be approached by enzyme redesign involves 
modification of an enzyme’s active site in order to accommodate different substrates 
(12).  This has been accomplished for lactate dehydrogenase where specificity for 
oxaloacetic acid over pyruvate is achieved.  In these studies, the active site was 
“redesigned” by first comparing the crystal structures for malate and lactate 
dehydrogenases in order to predict residues in the substrate binding site of lactate 
dehydrogenase that should be mutated for selection of oxaloacetic acid.  From these 
predictions, three single mutants of lactate dehydrogenase were generated, including 
mutations of Q102, D197, and T246 to arginine, asparagine, and glycine, respectively.  
For each single mutant, the catalytic efficiency for the alternative ligand, oxaloacetic 
acid, was increased.  It should be noted that lactate dehydrogenase is capable of using 
oxaloacetic acid as a substrate; however, the catalytic efficiency for oxaloacetic acid is 
1000 fold less than that for pyruvate.  Hence, the active site of lactate dehydrogenase was 
“evolved” to recognize oxaloacetic acid as a substrate over pyruvate (12, 13).    
 Can R67 DHFR be modified such that it recognizes an alternate substrate and 
catalyzes its reduction?  As a first approach to this objective, Howell and Chopra 
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(unpublished data) focused on the PTR1 catalyzed reaction.  PTR1 catalyzes the 
reduction of biopterin to dihydrobiopterin and dihydrobiopterin to tetrahydrobiopterin 
(14-16).  Interestingly, however, the enzyme is also capable of reducing folate to 
dihydrofolate and dihydrofolate to tetrahydrofolate (14-16).  In fact, the enzyme is 
proposed to be the cause of unsuccessful attempts at inhibiting DHFR using anti-folate 
drugs in clinical settings as the enzyme is able to catalyze the same reaction as DHFR 
without being inhibited by anti-folate inhibitors (17-19).   
 Comparisons of the PTR1 structure to that of R67 DHFR by Howell and Chopra 
yielded interesting results.  First, both enzymes are active as homotetramers possessing 
222 symmetry (2, 14).  Similar to the model proposed for R67 DHFR (1, 9, 10), NADPH 
comprises a major portion of the substrate binding site for PTR1 (14).  In fact, co-crystals 
of the complex PTR1-NADPH-MTX (methotrexate, a folate analog) indicate that 
"interactions between MTX and PTR1-NADPH occur principally at the pterin end of the 
drug and involve direct hydrogen bonds with the cofactor” (14).  This compares to NMR 
and X-ray crystallography studies for R67 DHFR which suggest that the rings of NADPH 
and DHF interact in the pore's center (2, 9).  In contrast to R67 DHFR, however, two 
active sites are present in PTR1(14).   
Based on the similarities between PTR1 and R67 DHFR and their substrates, 
Howell and Chopra asked the following question.  Is it possible to redesign R67 DHFR to 
catalyze the reduction of dihydrobiopterin using NADPH as its cofactor?  Preliminary 
experiments, performed by S. Chopra using the Quad 3 construct, suggest that R67 
DHFR can catalyze the reduction of dihydrobiopterin without the addition of point 
mutations.  Although this alternate activity is at present rather inefficient, point mutations 
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may be added to increase the efficiency of the reaction as was observed for the lactate 
dehydrogenase reaction (13).  The “hot spot” binding site of R67 DHFR (8) may be 
particularly suited for optimizing recognition of alternative ligands.    
  Another question that can be addressed by enzyme redesign involves modification 
of the enzyme’s preference for cofactor, specifically NADPH for NADH (12).  Again, 
this objective is greatly facilitated by structural information (12) and has been 
accomplished for glutathione reductase (20).  This enzyme recognizes NADPH as a 
cofactor.  Comparisons of glutathione reductase from two organisms indicated similar 
contacts between the two enzymes and NADPH.  Following addition of seven point 
mutations, preference for binding the alternate cofactor, NADH, was increased ~18000 
fold with respect to NADPH binding.  In these experiments, researchers generated 
mutations that would not only disfavor recognition of NADPH but would also favor 
recognition of NADH (12, 20).        
Can cofactor preference for R67 DHFR be modified?  R67 DHFR uses NADPH 
as a cofactor but can also catalyze the conversion of DHF to THF when NADH is 
supplied as the cofactor although the kcat/Km values for NAD(P)H and DHF are decreased 
~ 50 fold and ~ 18 fold respectively when NADH is added as the cofactor (7).  Since R67 
can use NADH as a cofactor, albeit inefficiently, we propose that the active site of R67 
DHFR may be “evolved” to select for NADH rather than NADPH.   
Salt studies on R67 DHFR suggest that K32 may be involved in an electrostatic 
contact with the 2′ phosphate of NADPH.  This interaction is likely involved in selection 
of NADPH over NADH (7).  Therefore, to alter the cofactor preference of R67 DHFR, it 
would be necessary to mutate K32 to a residue not capable of forming such interactions 
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with the 2′ phosphate.  As has been demonstrated previously, this solution is complicated 
by the symmetry of R67 DHFR in that mutation of each of the four K32 residues yields 
an inactive dimer (7).  In addition, generation of asymmetric K32M mutants still provides 
at least one wild-type K32 residue with which the cofactor may interact depending on the 
location of the mutations (Hicks et al., manuscript in preparation).  Therefore, to 
accomplish this goal it may be necessary to engineer the active site pore such that 
NADPH recognizes only one side of the pore.  Specifically, mutation of residues other 
than K32 on one side of the pore may be necessary in order to drive DHF binding to that 
side of the pore and NADPH binding to the opposite side of the pore.  Asymmetric 
mutagenesis of K32 residues only on the side of the pore with which NADPH would 
interact would then decrease the affinity of NADPH for the enzyme. 
Although it may be possible to decrease the affinity of NADPH through 
mutagenesis of specific K32 residues, in order to alter cofactor preference, it is necessary 
to simultaneously increase affinity for NADH.  Penning and Jez (12) maintain that “in 
nearly all cases elimination or introduction of basic residues that interact with the 2′-
phosphate of AMP of NADP(H) often in combination with additional mutations leads to 
successful conversion of cofactor preference” (12).  However, choosing the “additional 
mutations” for R67 DHFR where limited structural information defining cofactor 
interactions is available is complex.    
Docking studies suggest that, in addition to K32, Y69 may also play a role in 
providing contacts for the adenine ribose.  Specifically, the ring edge of Y69 is predicted 
to form contacts with one of the phosphate oxygens of the adenine ribose (8).  
Mutagenesis studies suggest that this interaction may be a charge-dipole interaction that 
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is decreased by mutagenesis of the tyrosine to phenylalanine (Stinnett et al., manuscript 
in preparation).  Could mutation of a Y69 residue(s) to a residue(s) capable of accepting a 
hydrogen bond facilitate selection for NADH over NADPH?  Again, this mutagenesis 
strategy is complicated by the symmetry of the enzyme.  Prior to mutating Y69 residues, 
it is likely necessary that additional residues be mutated such that one side of the pore 
prefers NADPH and the opposite side of the pore prefers DHF.  Both Y69 residues on the 
side of the pore selecting NADPH could then be mutated to residues capable of accepting 
a hydrogen bond.  Since the contact is between the ring edge of tyrosine 69 and the 
adenine ribose, a smaller hydrogen bond acceptor such as threonine may be capable of 
interacting with the 2′ hydroxyl group of NADH while disfavoring interactions with the 
2′-phosphate of NADPH.  As threonine has a smaller van der Waals volume than 
tyrosine, it is however possible that these mutations may disrupt packing interactions.  
Additional (or other) mutations may be engineered to select for NADH as more structural 
information regarding NADPH binding is obtained using NMR.         
A final question that may be approached using redesign of R67 DHFR is 
modifying the enzyme to catalyze other reactions (12).  One means by which to 
accomplish this is by “unmasking” additional activities catalyzed by the enzyme.  It has 
been suggested that several enzymes are capable of catalyzing other reactions.  However, 
the efficiency with which they do so is beyond that which is physiologically relevant (12, 
21).  When these alternate activities are observed, mutations can be engineered into the 
enzyme that promote catalysis of an alternate reaction (12).  This has been accomplished 
for the adenine glycosylase, MutY.  Mutation of a single serine residue in this enzyme to 
a lysine provides the enzyme with both glycosylase and lyase activities (12, 22). 
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Can R67 DHFR be redesigned to catalyze alternate reactions?  Interestingly, 
NMR studies performed to gain a better understanding of NADPH interactions in the 
active site revealed two additional activities catalyzed by the enzyme, a phosphatase 
activity and a transhydrogenase activity (23).  The first activity was observed as the time 
dependent appearance two resonances in the downfield portion of the NMR spectrum 
when NADP+ was incubated with the enzyme.  These resonances were most consistent 
with those of NAD+ suggesting a possible phosphatase activity for R67 DHFR.  In 
addition, chemical shift data also suggest that R67 DHFR is able to catalyze the transfer 
of a hydride ion from NADPH to an analog of NADP+, ADADP+ (3-acetylpyridine 
adenine dinucleotide phosphate).  The authors propose that K32 is involved in the former 
reaction but do not propose residues for involvement in the latter (23).  Without more 
structural information regarding the contacts between the ligands and the active site, 
proposing mutagenesis studies to redesign R67 DHFR to better catalyze these activities is 
not straightforward.  However, as more structural evidence is obtained via x-ray 
crystallography and NMR, the ability to redesign R67 DHFR to better catalyze these 
reactions is feasible. 
Due to its “hot spot” binding site (8), ability to use NADH as a cofactor (7), and 
ability to catalyze alternative reactions (23), we propose R67 DHFR as an ideal enzyme 
for redesign of an active site.  This is supported by evidence from Matsumura and 
Ellington (24) who observed a “non-specific intermediate” with “broadened specificity” 
during their attempts to change the activity of the enzyme, beta-glucuronidase.  However, 
successive rounds of mutagenesis and selection yielded an enzyme with specificity for 
the alternate ligand (24).  Based on the characteristics of R67 DHFR, it may be possible 
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to envision the enzyme as a type of “non-specific intermediate” in that it employs a “hot 
spot” binding mechanism (8) and can use NADH as a cofactor (7).  Therefore, with the 
appropriate mutagenesis strategies, it may be possible to alter the properties of R67 
DHFR such that it is able to recognize alternate ligands and catalyze other reactions. 
How will these studies be important to the field of enzymology?  First, they will 
provide a greater understanding of the means by which enzymes catalyze reactions.  
Specifically, they will provide more information regarding the types of scaffolds that are 
necessary for recognition of alternate substrates and catalysis of new reactions.  In 
addition, these experiments are important from a pharmaceutical and industrial 
perspective as enzymes are redesigned to catalyze novel reactions (12). 
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